Real-time PCR analysis of age-dependent alterations in the RVLM neurotransmitter gene expression profile of F344 rats by Craig, Robin Ann
 REAL-TIME PCR ANALYSIS OF AGE-DEPENDENT ALTERATIONS IN THE RVLM 
NEUROTRANSMITTER GENE EXPRESSION PROFILE OF F344 RATS 
 
by 
 
 
ROBIN ANN CRAIG 
 
 
B.S., Kansas State University, 1999 
M.S., Kansas State University, 2001 
 
 
 
AN ABSTRACT OF A DISSERTATION 
 
 
submitted in partial fulfillment of the requirements for the degree 
 
 
DOCTOR OF PHILOSOPHY 
 
 
Department of Anatomy and Physiology  
College of Veterinary Medicine 
 
 
 
 
 
 
 
KANSAS STATE UNIVERSITY 
Manhattan, Kansas 
 
 
2007 
 
 Abstract 
 
It is well established that normal aging is associated with progressive increases 
in efferent sympathetic nerve discharge (SND). Type II diabetes, obesity, heart failure, 
and hypertension are pathologies that have been attributed to both the processes of 
aging and sympathetic dysfunction, exemplifying the importance of understanding 
central regulation of SND during aging. However, the central mechanisms mediating 
altered SND with advancing age remain unclear. The rostral ventral lateral medulla 
(RVLM) is a brainstem region critically involved in setting the basal level of sympathetic 
outflow and cardiovascular function. Indeed, the RVLM is the only presympathetic 
region that when bilaterally inactivated results in profound reductions in both SND and 
arterial pressure. Glutamatergic influences in RVLM activity are powerfully inhibited by 
tonic GABAergic neural inputs originating from the caudal ventral lateral medulla 
(CVLM); effects that are mediated by GABAA receptors located on presympathetic 
neuronal cell bodies within the RVLM. In the present study we proposed that reductions 
in GABAA receptor subunit gene expression may reflect withdrawal of GABAergic tone 
in the RVLM thereby contributing to the basal sympathetic activation that occurs with 
advancing age. Therefore, the objective of the current study was to identify age-related 
changes in the constitutive expression of genes related to GABAergic and muscarinic, 
nicotinic and dopaminergic receptor systems due to their reported involvement in 
modulating GABAA receptor function, in the RVLM of adult young (3-5 mo. old), middle-
aged (12 mo. old), weight stable presenescent (24-25 mo. old) and senescent (>24 mo. 
old) Fischer 344 (F344) rats using a commercially available real-time PCR array. Real-
time analysis revealed nonuniform and age-associated changes in the RVLM GABA, 
muscarinic, nicotinic and dopaminergic neurotransmitter gene expression profile 
 between young and middle-aged F344 rats. Heterogenous expression of genes related 
to these neurotransmitters was also observed between presenescent and senescent 
F344 rats. Our results suggest that potential changes in neurotransmitter synthesis and 
degradation, uptake, transport, signaling and receptor subunit composition may account 
for the sympathoexcitatory state that is commonly observed in the aged. 
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modulating GABAA receptor function, in the RVLM of adult young (3-5 mo. old), middle-
aged (12 mo. old), weight stable presenescent (24-25 mo. old) and senescent (>24 mo. 
old) Fischer 344 (F344) rats using a commercially available real-time PCR array. Real-
time analysis revealed nonuniform and age-associated changes in the RVLM GABA, 
muscarinic, nicotinic and dopaminergic neurotransmitter gene expression profile 
between young and middle-aged F344 rats. Heterogenous expression of genes related 
to these neurotransmitters was also observed between presenescent and senescent 
F344 rats. Our results suggest that potential changes in neurotransmitter synthesis and 
degradation, uptake, transport, signaling and receptor subunit composition may account 
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CHAPTER 1 - Cellular Biology of Brain Aging 
The cellular mechanisms mediating the aging process are highly complex and 
despite extensive investigative efforts, aging remains a poorly understood process. 
However, it is generally agreed that cellular mechanisms largely contribute to the 
gradual and progressive deleterious alterations in critical physiological processes that 
occur with advancing age23-32.  Understanding aging of the brain is of particular interest 
because the brain provides the foundation for centrally-mediated regulation of essential 
physiological processes involved in the maintenance of homeostasis and the generation 
of adaptive responses to stress33-35.   
 
The biological and physiological consequences of brain aging have generated 
substantial interest within the research community due to the association of advancing 
age with neurodegenerative diseases including Alzheimer’s, Parkinson’s and 
amyotrophic lateral sclerosis (ALS)24,28,36-41, with particular focus on understanding 
molecular factors that contribute to the physiological heterogeneity commonly observed 
among aged individuals. It is unclear, for example, what underlying mechanisms 
are responsible for an individual’s increased susceptibility to the development 
and progression of certain neurodegenerative diseases or to the development of 
other centrally-mediated age-associated pathologies including hypertension. This 
is of critical importance because it is estimated that globally, the number of aged 
persons between 60 and 80 years or over will increase over eight-fold by 205042. It 
has been suggested that such variable responses to aging may be attributed to cellular 
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mechanisms such as errors in protein processing, genetic mutations, or defective repair 
mechanisms, all of which either independently or in combination may damage the cell, 
tissue or organ. Therefore, the mechanisms of aging are likely to have both a genetic 
and a molecular component. Indeed, age-associated reductions in cellular metabolism 
and oxygen consumption28,30,43, DNA repair mechanisms31,44, protein synthesis25,45-48, 
and specific neurotransmitters24,49; and increases in glycation end-products25,27,31,50-52, 
oxidative damage53-55 to membrane lipids24,32,36,56-58, proteins and DNA24,32,59-61, and the 
accumulation of protein aggregates27,62,63 have all been widely reported, a number of 
which have also been described in the brain. Such age-related alterations provide the 
foundation for over 300 theories of aging32, demonstrating the significant investigative 
effort currently directed towards understanding the basic cellular mechanisms that 
mediate the complex process of brain aging.  
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CHAPTER 2 - The Sympathetic Nervous System 
Figure 2.1 Sympathetic and Parasympathetic Arms of the 
Autonomic Nervous System1. Efferent nerves (outflow from 
the brain and spinal cord) and afferent nerves (incoming 
sensory information from the periphery) provide a link 
between the central nervous system and visceral effector 
organs, respectively, thereby providing the functional 
foundation of the autonomic nervous system4. The 
sympathetic nervous system is responsible for the 
generation of adaptive physiological responses during 
periods of rest, stress or life-threatening challenges 
whereas the parasympathetic nervous system is involved 
in physiological recovery in response to such situations11.  
The autonomic nervous system plays a critical role in maintaining physiological 
homeostasis under basal conditions and in response to stressors and life-threatening 
situations11,33-35. While the 
autonomic nervous system 
includes both the sympathetic 
(“fight or flight”) and 
parasympathetic (“rest and 
digest”) nervous systems, it is 
the sympathetic nervous 
system that is involved in the 
central regulation of 
coordinated adaptive 
physiological responses to 
stress through the tonic 
activation of sympathetic 
nerves that innervate the heart, 
blood vessels, muscle, lungs, adrenal medulla and liver (figure 2.1)64. Therefore, 
sympathetic activation is generally associated with increased heart rate and force of 
myocardial contraction, peripheral vasoconstriction, blood flow to skeletal muscle, 
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bronchodilation, release of the “stress hormone” cortisol from the adrenal gland and 
energy metabolism64.  
 
Centrally-mediated changes in the level or pattern of efferent sympathetic outflow 
in response to an acute stressor are a primary means by which mammals maintain 
homeostasis65-68; however, aging is known to substantially alter sympathetic nerve 
responses to a variety of stressors including heat stress65,69,70, cold stress71, hypoxia72,73 
and footshock74. Sympathetic dysregulation is also associated with type II diabetes75-82, 
irritable bowel syndrome83-86, hypertension87, obesity88-92, chronic heart failure93-96, 
insulin resistance75,82,97, and metabolic syndrome88,92, the incidence of which are all 
known to increase with advancing age. Therefore, it is has been hypothesized that 
sympathetic dysfunction may contribute in large part to the increased 
susceptibility of aged individuals to environmental stressors and to the 
development of many age-related disease states, thereby highlighting the critical 
need to understand the neural mechanisms underlying alterations in centrally-mediated 
sympathetic activity that occur during normal aging. 
 
Central Autonomic Pathway Organization: Descending Neural Projections  
Generation of sympathetic nerve activity occurs along multiple levels of the 
neuraxis and involves reciprocal neural connections between the forebrain, brainstem 
and spinal cord4,34 (figure 2.2). Sympathetic nerve outflow is directly mediated by 
descending neural pathways whose cell bodies are contained in various autonomic 
nuclei of the forebrain and brainstem33-35 (figure 2.2). Indeed, the neural efferents that 
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project from these brain regions, referred to as presympathetic neurons, are considered 
to be the final central output directly involved in the modulation of physiological 
responses to internal and environmental stimuli4,6,33,34. Anatomical and neurochemical 
studies have demonstrated that glutamatergic presympathetic neurons project to the 
thoracolumbar intermediolateral cell column of the spinal cord (IML) and innervate 
preganglionic neurons4,6,33-35 which in turn, synapse with noradrenergic-containing 
postganglionic neurons that directly innervate effector organs (figures 2.1, 2.2).  
 
 
 
 
 
 
 
 
 
 
 
 Figure 2.2. Descending Neural Projections Regulating 
Sympathetic Outflow4.  
 
 
In all vertebrates studied, sympathetic postganglionic neurons in vivo exhibit 
spontaneous, low levels of maintained (tonic) activity34. Synaptic activity is commonly 
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characterized by the presence of synchronized discharge bursts which contain a 
prominent cardiac-related component in animals with intact baroreceptors98,99. The 
entrainment of sympathetic nerve activity to the cardiac cycle (systolic and diastolic 
phases) provides the mechanism by which SND bursting patterns are “locked” 1:1 in 
relation to the arterial pulse - a hallmark of the cardiac-related discharge pattern. As 
figure 2.3 demonstrates, in baroreceptor-innervated animals an inverse relationship 
exists between efferent sympathetic bursts (figure 2.3, top) and the arterial pulse (figure 
2.3, bottom), such that decreases in blood pressure (BP) during the diastolic phase of 
the cardiac cycle elicit the immediate potentiation of sympathetic outflow to the heart, 
peripheral vasculature, adrenal gland, lumbar region of the spine, kidney (figure 2.3A) 
and spleen (figure 2.3B)68.  
Figure 2.3. Cardiac-related Sympathetic Bursting Patterns7. Discharge bursts related to the 
arterial pulse are observed during single nerve recordings of postganglionic renal (A) and
splenic (B) nerve fibers in the cat7. Cardiac-related rhythms have been demonstrated in many 
species, including humans, and are unaffected by the presence of anesthesia4,6,7,16,18-20. 
However, the correlation between the cardiac cycle and basal sympathetic nerve discharge
bursts is virtually eliminated following removal of baroreceptor afferents, demonstrating an intact
baroreflex is required for the generation of sympathetic activity that is coupled to the arterial 
pulse21,22.    
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Although cardiac-related rhythmicity is considered a hallmark of most 
sympathetic nerves under conditions where baroreceptors remain intact98,99, some 
sympathetic nerves, including those innervating brown adipose tissue (BAT) and skin do 
not display spontaneous, cardiac-related rhythmicity100-104. Therefore, sympathetic 
nerve discharge rhythmicity and patterns (e.g., duration and interval) may be considered 
non-uniform in nature6,100, dependent in part, on the animal being studied (cat, human, 
rat103,105,106), its’ physiological state at the time of direct nerve recording (advanced age, 
hypertension, cold or heat stress, heart failure, diabetes), and the type of nerve being 
recorded11,103,105,106 (BAT, skin, sweat gland, kidney, adrenal gland, tail).  
 
Sympathetic Nerve Discharge Patterns and Regulation of Organ Function 
Sympathetic nerve discharge plays an important role in the regulation of 
essential physiological functions involved in the maintenance of homeostasis, although 
frequently the physiological relevance of oscillatory patterns displayed by a specific 
nerve is unclear100. Gebber and coworkers107,108 have suggested that compared to 
random discharge bursts, rhythmic SND may provide a mechanism by which more 
effective neurotransmission and complex, highly differentiated physiological response 
patterns may be generated in response to a variety of stressors or in an effort to 
maintain physiological homeostasis.  
 
Physiological response properties specific to a particular sympathetic 
postganglionic nerve or to its discharge bursting pattern have primarily been 
characterized by the direct recording of nerve activity in anesthetized animal 
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preparations. Insight into the functional specificity of sympathetic nerves is commonly 
accomplished by correlating alterations in the level or pattern of sympathetic nerve 
discharge with a specific end-organ function. For example, physiological experiments 
conducted by our laboratory routinely involve direct whole nerve recordings of 
sympathetic postganglionic axons that innervate the kidney and spleen because 
sympathetic innervation of the kidney and spleen are highly involved in the physiological 
processes of renal blood flow, renin release, glomerular filtration rate, salt and water 
retention and provide a direct, neural link between the immune system and central 
nervous system, respectively. Physiological processes such as these are mediated in 
part by tonic synchronized sympathetic neural input, the physiological relevance of 
which is briefly described below.  
 
Kidney. The kidney is critically involved in the support of arterial pressure 
through sympathetic-mediated adjustments in blood volume and composition33. 
Adjustments are achieved by sympathetic postganglionic innervation of the 
juxtaglomerular apparatus, glomerulus, and epithelial cells of the nephron and renal 
vasculature. It has been demonstrated that cardiac-related sympathetic discharge 
patterns elicit increases in renin release, decreases in glomerular filtration rate, 
increased water and solute absorption and decreased renal blood flow, respectively33, in 
an effort to maintain proper blood volume and pressure. In contrast, under conditions 
where cardiovascular homeostasis has been achieved, baroreceptor afferent-mediated 
inhibition of efferent renal SND results in the attenuation of renin release and renal 
tubular transport of solutes and water, and increases in renal blood flow and glomerular 
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filtration rate.  Therefore, synchronization of renal postganglionic nerve discharge bursts 
is important for the generation of coordinated renal responses necessary for the 
maintenance of arterial pressure.  
 
Spleen. The spleen is involved in a bi-directional communication pathway that 
exists between the central nervous system and the immune system109-111. Sympathetic 
innervation of the spleen modulates important immune system function including splenic 
T and B cell proliferation112-114, natural killer cell activity112,113, splenic production of 
immunoglobulin M115, and splenic cytokine and chemokine gene expression116,117.  
Ganta and coworkers116 demonstrated that acute bouts of hyperthermia transforms the 
cardiac-related bursting pattern of SND observed under control conditions (38°C) to a 
pattern that contains low frequency and non-cardiac-related bursts at 41.5°C. Of 
particular interest is that the increases in splenic nerve activity and pattern 
transformation observed at 41.5°C were associated with enhanced IL-1β, IL-6 and GRO 
1 mRNA expression in the spleen. While it is unclear whether splenic transcriptional 
responses were the result of alterations in the level or pattern of splenic nerve discharge 
at 41.5°, the upregulation of these genes was abolished following splenic denervation. 
These results indicate that the transcriptional upregulation of splenic IL-1β, IL-6 and 
GRO 1 is dependent on sympathetic innervation of the spleen during acute bouts of 
hyperthermia. 
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CHAPTER 3 - Central Regulation of Sympathetic Nerve 
Activity and Cardiovascular Function 
 
Figure 3.1. Supraspinal Neurons
Synapse With Preganglionic Neurons4,20. 
Although a number of autonomic centers
exist in the brain, only a few contain the
cell bodies of presympathetic neurons
whose axons project directly to the spinal
cord and innervate preganglionic
neurons4,6,15,16. Evidence suggests that
supraspinal inputs play an important role
in the regulation of cardiovascular
function including the maintenance of
arterial pressure17.  
It is well established that the highly coordinated and integrated regulation of 
sympathetic nerve discharge involves numerous regions of the brain; including the 
paraventricular nucleus of the hypothalamus, 
A5 noradrenergic cell group, rostral ventral 
lateral medulla, ventromedial medulla, and 
caudal raphe nuclei20. Each of these brain 
regions contain the cell bodies of 
presympathetic neurons whose axons directly 
synapse with preganglionic neurons in the IML 
of the spinal cord20 (figure 3.1). Indeed, several 
lines of evidence support the role of supraspinal 
neural inputs in the generation of SND 
rhythms18 and the maintenance of arterial blood 
pressure4,6,15,16. Several experimental methods 
exist to determine supraspinal involvement in 
specific physiological functions, many of which 
involve neuronal inactivation18 or transection at 
include chemical inactivation (kainic acid, muscimol, kynurenic acid, lidocaine) and 
physical inactivation of presympathetic neurons (midbrain transection, cervical 
multiple levels of the neuraxis. Such methods 
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transection). A variety of these methods have primarily been used to determine 
supraspinal neural circuit involvement in cardiovascular function and regulation of 
efferent SND. For example, spinal transection at the level of the first cervical vertebrae 
(C1) elicits profound reductions in mean arterial pressure (MAP) at levels similar to that 
following ganglionic blockade (prevents synaptic transmission from preganglionic 
neurons to postganglionic neurons) and removes the rhythmicity that is characteristic of 
most sympathetic postganglionic neuronal activity118-120, strongly suggesting a 
prominent role of tonic supraspinal support in the regulation of cardiovascular 
function6,16,121,122 and the modulation of efferent sympathetic nerve discharge 
patterns18.  
 
Regulation of Sympathetic Nerve Outflow: the RVLM 
The traditional view is that that the central neurons mediating sympathetic 
outflow to the heart and vasculature (vasomotor neurons) are distributed throughout the 
of forebrain neural circuits by midbrain transection 
fails to significantly alter resting levels of MAP , 
suggesting a role of brainstem autonomic nuclei in 
the regulation of cardiovascular function. Such a 
role has been established for the rostral ventral 
lateral medulla (RVLM), a brainstem site that is 
critically involved in setting the level of basal 
sympathetic activity  of postganglionic nerves that 
innervate the heart  and a number of other effector organs including the peripheral 
brainstem6,121-125 because removal 
66
18
126,127
Figure 3.2. Anatomical Location of 
the RVLM6. Landmarks used to 
identify the location of the RVLM 
include the facial motor nucleus (7), 
nucleus ambiguus (NA) and pre-
6Bötzinger complex . 
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vasculature , kidney , spleen  and adrenal gland  through the 
direct regulation of spinal-projecting presympathetic nerves . The level of basal 
sympathetic nerve activity is largely determined by a functional balance of both 
excitatory and inhibitory neural inputs to the RVLM . Such neural modulation 
of RVLM activity plays an integral role in the support of arterial pressure  and 
the generation of adaptive physiological responses to internal and environmental 
stressors . Located immediately caudal to the posterior end of the facial motor 
nucleus (7), ventral to the nucleus ambiguous (NA) and Bötzinger complex, and rostral 
to the pre-Bötzinger complex  (figure 3.2), the role of the RVLM in cardiovascular 
function was first demonstrated by Dittmar in 1873. In this landmark study, bilateral 
destruction of a discrete portion of the ventral medulla was found to produce a marked 
reduction in arterial pressure . Several lines of evidence provide additional support for 
the involvement of the RVLM in the modulation of vasomotor tone and the maintenance 
of arterial pressure. First, retrograde transport studies revealed a direct monosynaptic 
neural projection from the RVLM to the IML of the spinal cord  indicating direct 
innervation of preganglionic neurons (figures 2.2, 3.1). Second, direct surface 
application of the inhibitory amino acids γ-aminobutyric acid (GABA)  or glycine , or 
cooling  of the ventral areas of the medulla elicits significant reductions in arterial 
pressure. Third, in contrast to the medullary administration of GABA or glycine, 
electrical and chemical stimulation of the RVLM induces rapid and marked increases in 
arterial pressure and heart rate . Fourth, chemical lesions of the RVLM 
permanently lowers arterial pressure in conscious and unrestrained dogs  while in 
decerebrate (midbrain-transected) anesthetized cats inhibition of RVLM neurons by 
128-133 4,128,130,134 135 128,130,136,137
138,139
128,129,140-145
3,128,129,146
134,147-151
6,152,153
123
154,155
6 156,157
158
159-162
163
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unilateral microinjections of muscimol, a GABA  receptor agonist, results in significant 
and lasting reductions in MAP . Importantly, the RVLM is the only presympathetic 
region that when bilaterally chemically inactivated results in profound reductions 
in both arterial pressure and sympathetic nerve activity , demonstrating its critical 
role in mediating the activity of postganglionic neurons that innervate the heart and 
other effector organs through the regulation of presympathetic nerve outflow. In 
contrast, experimental modulation or inactivation of supraspinal neurons in the midline 
medulla, A5 area, or paraventricular nucleus of the hypothalamus (PVN) does not result 
in significant reductions in resting arterial pressure or sympathetic activity . 
Therefore, although these autonomic centers are similar to the RVLM in that they 
contain spinal-projecting presympathetic neurons, centrally-mediated support of arterial 
pressure and determination of the level of basal sympathetic nerve discharge appears 
to be primarily mediated by the RVLM . Indeed, the RVLM is considered to be 
perhaps the single most important source of tonic excitatory drive to 
presympathetic neurons involved in the maintenance of arterial pressure and at 
present is the only autonomic region ide
A
164
129
165,166
18
ntified as being critically involved in the 
integration of cardiovascular reflexes4.  
Au
 
tonomic Regulation of Sympathetic Nerve Outflow: Influence of the Baroreflex 
Blood pressure is influenced by peripheral vascular resistance and cardiac 
output, both of which are tightly controlled by the autonomic nervous system167. Short 
term maintenance of arterial blood pressure within normal limits is achieved by the 
baroreflex arc that involves the afferent projections of arterial baroreceptors that 
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originate in the walls of the aortic arch, carotid sinus, atria and ventricles and project to 
supraspinal cardiovascular autonomic nuclei in the brain (figure 3.3). Thus, the 
baroreflex represents a negative feedback signaling mechanism by the heart and brain 
modulates blood pressure and sympathetic nerve outflow in response to the arterial 
pulse. 
are modulated primarily by a cardiovascular auto
 
 
The baroreflex and therefore, tonic cardiac-related sympathetic neuronal activity 
nomic complex involving the nucleus of 
the solitary tract (NTS), caudal ventral 
lateral medulla (CVLM) and RVLM128 
(figure 3.3). However, the RVLM is 
considered to play a critical integrative 
role in facilitating the generation of 
physiological responses to neural 
inputs that arise from the periphery and 
from autonomic nuclei located at higher 
levels along the neuraxis4. It is also 
considered to be the predominant source of excitatory drive to barosensitive 
presympathetic neurons7,18,19,65-68,168,169. Therefore, the neural circuitry that comprises 
the baroreflex arc provides a highly regulated mechanism by which the arterial pulse 
may influence sympathetic nerve activity such that increases in blood pressure during 
the systolic phase of the cardiac cycle (contraction) elicit centrally-mediated dilation of 
the peripheral vasculature, reductions in cardiac contractile force and heart rate, and 
Figure 3.3. The Baroreflex Arc3. The baroreflex is
considered to be the most important mechanism
for centrally-mediated short term regulation of
arterial blood pressure . 12-14
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baroreceptor-mediated inhibition of RVLM presympathetic neurons3,6,122,129,146,170-172 
(figures 2.3, 3.4  illustrate baroreflex-mediated inhibition of postganglionic nerve 
activity).  
 
 
Cardiac-Related Sympat ursts Are Dependent on Intact 
Figure 3.4.  Baroreflex-mediated inhibition of Renal SND.  Pharmacological activation of 
baroreceptor afferents is achieved by the intravenous administration of phenylephrine, a 
vasoconstrictive agent that is commonly used to measure arterial baroreflex function.  Our
laboratory has demonstrated that increases in blood pressure in response to phenylephrine
administration markedly inhibits sympathetic outflow to the kidney, indicating baroreceptor-
mediated inhibition of sympathetic nerve activity (R. Fels, unpublished data). 
hetic Nerve Discharge B
Baroreceptor Afferents 
 
The role of the baroreflex in modulating blood pressure and cardiac-related 
sympathetic bursting patterns may be clearly demonstrated under experimental 
conditions whereby afferent baroreceptors are removed from the aortic arch and carotid 
region of the heart. Figure 3.5 demonstrates the effect of sinoaortic denervation (SAD; 
removing baroreceptor afferents to the brainstem) on blood pressure and the cardiac-
locked activity of postganglionic nerves innervating the kidney and spleen. Our 
laboratory and others have demonstrated that SAD increases blood pressure17,65,173, 
heart rate17,65 and the level of sympathetic outflow to a number of effector organs17,65,174-
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176 including the kidney and spleen, compared to baroreceptor-intact animals. As figure 
3.5 demonstrates, following SAD the cardiac-related rhythm of renal and splenic 
postganglionic nerves is strikingly eliminated - a pattern that is not present in 
baroreceptor innervated animals which exhibit a 1:1 SND bursting pattern in relation to 
the arterial pulse (e.g., SND bursts only during the diastolic phase of the cardiac cycle 
when MAP is low) (figures 2.3, 3.5). It is clear, therefore, that baroreceptor input to the 
brainstem is required for the entrainment of presympathetic neurons to the arterial 
pulse. 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Effect of SAD on SND and MAP. In our laboratory animals in 
which baroreceptor afferents remain intact exhibit sympathetic nerve 
discharge bursts that are locked 1:1 in relation to the arterial pulse while the
removal of baroreceptor afferents (SAD) eliminates this cardiac-related 
rhythm, demonstrating the requirement of the baroreflex in contributing to the
cardiac-related rhythmicity of sympathetic nerves in baroreceptor-intact 
animals (R. Fels, unpublished data).   
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CHAPTER 4 - Modulation of RVLM Activity: Inhibitory 
Neurotransmitter Mechanisms 
 
The RVLM is the only autonomic region identified as being critically involved in 
the integration of cardiovascular reflexes4. Because it is well established that under 
basal conditions tonic RVLM presympathetic neural activity is strongly suppressed by 
GABAergic influences177-179, neurotransmitter-
mediated modulation of RVLM presympathetic 
nerve activity is expected to play an important 
role in the integration of reflex responses for 
several reasons. First, the RVLM contains the 
highest concentration of presympathetic 
neurons144,180-183, demonstrating its role as the 
final point of centrally-regulated sympathetic 
nerve outflow. Second, short term stabilization 
of blood pressure and attenuated RVLM 
presympathetic nerve activity in response to 
baroreflex activation is achieved through 
withdrawal or enhancement of the RVLM 
GABAergic neurotransmitter system. Several 
lines of evidence demonstrate the importance of 
Figure 4.1. RVLM GABA Inhibits 
Sympathetic Outflow. Our laboratory has 
demonstrated that microinjection of a 
GABAA receptor antagonist (BIC) or 
agonist (MUSC) into the RVLM 
potentiates or attenuates SND, 
respectively, demonstrating that GABA 
exerts its inhibitory influence through 
GABAA receptors. Percent changes for 
renal and splenic SND were combined 
and averaged per treatment timepoint (R. 
Fels, unpublished data). 
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GABAergic neural inputs to the RVLM in influencing basal sympathetic nerve activity. 
Removal of inhibitory influences with the GABAA receptor antagonist bicuculline (BIC) 
elicits immediate increases in the firing rate and level of SND177,179,184-186 (figure 4.1) 
and MAP184-187 (figure 4.2), indicating that GABA exerts a substantial influence on 
RVLM-mediated resting levels of SND and MAP. Furthermore, inhibition of local GABA 
synthesis within the RVLM by 3-mercaptopropionic acid (a glutamate decarboxylase 
inhibitor) increases MAP, demonstrating that endogenous GABA strongly inhibits RVLM 
vasomotor activity under resting conditions185. Collectively, these studies demonstrate 
that within the RVLM, endogenous GABA plays an essential role in the central 
baroreflex pathway because removal of tonic GABAergic influences attenuates 
baroreflex-dependent inhibition of RVLM-mediated SND (both vasomotor and 
presympathetic) and arterial pressure responses172,177,179,186,187.   
 
 
 
 
 
 
 Figure 4.2. RVLM GABA Reduces
Arterial Pressure. We have demonstrated 
that microinjections of bicuculine (BIC) 
and muscimol (MUSC) directly into the 
RVLM elicit pressor and depressor 
responses, respectively. These results 
indicate that RVLM support of arterial 
pressure is mediated in part by GABAA
receptors located on neuronal cell bodies 
within the RVLM (R. Fels, unpublished 
data). 
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The CVLM Mediates GABAergic Inhibition of RVLM Vasomotor and Presympathetic 
Neurons 
The CVLM contributes to tonic GABAergic inhibition of the RVLM such that 
stabilization of blood pressure is achieved through the phasic withdrawal or 
enhancement of CVLM GABAergic tone on RVLM barosensitive vasomotor sympathetic 
neurons through both baroreceptor-dependent and independent mechanisms3,146,188-191. 
Located 1.0-1.5mm caudal to the RVLM in the rat172, the depressor neurons of the 
CVLM are located primarily between the nucleus ambiguous and the lateral reticular 
nucleus although landmarks such as the facial nucleus, obex, and calamus scriptorius 
are often used for reference6,172,192,193 (see figure 3.2 for illustration of landmarks). Such 
close proximity to cell bodies of presympathetic neurons in the RVLM does not allow for 
clear distinction between excitatory presympathetic neurons in the RVLM or inhibitory 
neurons in the CVLM194,195. However, retrograde tracing and anatomical studies have 
successfully established distinct, monosynaptic projections from the CVLM to the 
RVLM1,4,181,182,189,190,196-199.  
 
The role of CVLM GABAergic neurons as a source of tonic inhibition of RVLM 
spinal-projecting neurons has received much attention6,191,200. It is well established that 
the CVLM inhibits RVLM presympathetic and vasomotor nerve outflow167 in order to 
elicit reductions in SND and MAP172. Such alterations in MAP are achieved through 
RVLM-mediated reductions in total peripheral resistance, cardiac contractility160,196,201,202 
and blood flow to the vasculature of the kidney, mesentery and hindlimb160. 
Microinjection studies have demonstrated that the activity of the CVLM may be 
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attenuated or potentiated by CVLM application of muscimol (MUSC; GABAA receptor 
agonist) or glutamate, respectively. For example, inhibition of neural cell bodies within 
the CVLM by MUSC microinjection increases MAP and SND184,203 (figure 4.3; SAD) at 
levels similar to those observed following GABAA receptor blockade 
in the RVLM184,203, suggesting that the CVLM inhibits efferent SND 
primarily through direct GABAergic neural inputs to the 
RVLM177,203,204. Antagonism of RVLM GABAA receptors with BIC 
prevents reductions in MAP and SND in response to glutamatergic 
stimulation of the CVLM171,205-207, further demonstrating that 1) the 
CVLM provides a powerful source of tonic inhibition to the RVLM, 2) 
depressor and attenuated SND responses to CVLM stimulation are 
largely mediated by the RVLM and 3) tonic inhibitory neural inputs to the RVLM from the 
CVLM are mediated by GABAA receptors4,177,190,205,208-212.  
Figure 4.3.
Inactivation of the 
CVLM Potentiates 
Splenic SND (R. 
Fels, unpublished 
data).  
 
Microinjection studies conducted in the rat and rabbit in which glutamate was 
directed into the CVLM have demonstrated marked reductions in RVLM presympathetic 
SND193,213,214 and MAP159,193,215 (figure 4.4), suggesting that glutamatergic excitation of 
the CVLM is responsible for the SND and depressor responses observed following 
CVLM activation201,205,216,217. In contrast, chemical blockade of CVLM glutamate 
receptors attenuates GABAergic inhibition of RVLM neurons in response to increases in 
MAP or direct stimulation of the NTS210,216,218,219, indicating that the CVLM is the 
principle component involved in providing direct inhibitory neural inputs to the RVLM. 
Collectively, these microinjection studies in which the molecular mechanisms of CVLM-
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mediated GABAergic inhibition of RVLM sympathetic outflow were examined highlight 
the importance of RVLM GABAA receptors and demonstrate the complexity of the 
neural network regulating RVLM sympathetic outflow and related physiological 
responses.  
 
 
 
 
 
 Figure 4.4. CVLM-mediated GABAergic Reductions in SND and Blood 
Pressure Are Dependent on Glutamate. Preliminary experiments completed 
in our laboratory demonstrate that CVLM glutamate microinjections markedly
reduce splenic SND and blood pressure, indicating that glutamatergic neural
inputs to the CVLM are the mechanism which supports CVLM-induced 
inhibition of efferent SND and tightly controls fluctuations in blood pressure
(R. Fels, unpublished data). 
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CHAPTER 5 - The RVLM GABAergic Neurotransmitter 
System 
 
RVLM-mediated regulation of sympathetic nerve activity is modulated by a 
variety of neurotransmitter systems including GABA, glutamate, serotonin, substance P, 
neuropeptide Y, glycine, angiotensin II, and somatostatin6. Spinal-projecting 
presympathetic neurons in the RVLM have been reported to express these 
neurotransmitters6,220-223, suggesting that these neurotransmitters are involved in the 
regulation of efferent sympathetic nerve activity. However, it is well established that 
under basal conditions tonic RVLM presympathetic neural activity is strongly 
suppressed by GABAergic influences177-179 originating in large part from the 
CVLM6,167,172,191,200 and that such inhibition is mediated by GABAA 
receptors4,172,177,179,186,205.  This section provides a brief overview of the inhibitory 
neurotransmitter GABA and its ionotropic receptor subtype, GABAA, in relation to 
GABAergic regulation of central neuronal synaptic transmission.  
 
GABA 
GABA (γ-aminobutyric acid) is the major inhibitory neurotransmitter in the 
brain224-226 and GABAA receptors (GABAAR) mediate the majority of fast inhibitory 
synaptic transmission in the central nervous system225,227, including the RVLM. 
Activation of GABAAR elicits a rapid rise in intracellular levels of chloride, resulting in 
hyperpolarization of the postsynaptic neuronal membrane and the inhibition of 
postsynaptic currents228,229. Such powerful tonic GABAergic control of neuronal 
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excitability has been demonstrated in our laboratory following the microinjection of 
MUSC directly into the RVLM, which produces marked reductions in splenic and renal  
sympathetic nerve activity (figures 4.1, 5.1) and arterial pressure (figure 4.2) are 
observed. 
 
 
 
 Figure 5.1. RVLM Muscimol Microinjection 
Reduces Renal SND. Experiments 
completed in our laboratory have
demonstrated that microinjection of the 
GABAA receptor agonist muscimol (MUSC)
into the RVLM mimics CVLM-mediated 
GABAergic inhibition of SND (R. Fels, 
unpublished data). 
 
 
 
 
GABAA Receptors. GABAAR are members of the ligand-gated ion channel superfamily 
that includes nicotinic acetylcholine, glycine, glutamate and serotonin receptors230. X-
ray crystallography studies of acetylcholine-binding protein, a protein resembling the 
extracellular ligand-binding domain of the nicotinic acetylcholine receptor, have provided 
insight into the predicted structure and identification of five separate binding sites 
located on the GABAA receptor including, GABA (represented by white filled circles, 
figure 5.2), benzodiazepines (represented by black filled circle, figure 5.2), barbituates, 
the chloride channel blocker picrotoxin, and anesthetics9,231-235. Similar expression 
studies have indicated that the GABAA receptor is composed of a fixed pentameric 
subunit arrangement of beta-alpha-beta-alpha-gamma9,236-239 (figure 5.2), and that a 
combination of alpha, beta and gamma GABAAR subunit variants are required for the 
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expression of fully functional and membrane localized GABAA receptors237,240,241. 
Individually, GABAA receptor subunits mediate specific aspects of GABAA receptor 
function. For example, GABAA receptor alpha subunits contribute to the formation of the 
high affinity GABA binding pocket242,243 and determine GABAAR 
pharmacological properties in response to benzodiazepines243-
248. Beta subunits are required for GABAA receptor cell surface 
expression249-251 and GABA binding244,245,248,252. Gamma subunits 
influence GABAA receptor cell surface expression253,254 and 
synaptic clustering255. Individual GABAA receptor subunit variants are differentially 
expressed, thereby potentially contributing to region-specific functions of certain 
GABAAR subtypes. Alpha1 is the most widely distributed GABAA receptor subunit in the 
brain256 and radioligand binding and immunohistochemical studies have indicated that 
at least 50% of all GABAA receptors purified from rat brain contain the gamma2 subunit, 
40% of which associate with beta2 or beta3 subunits257. It has also been reported that 
90% of rat brain GABAA receptors contain beta2 or beta3257. Importantly, the rat RVLM 
reportedly expresses alpha1-3, beta2-3, and gamma2 GABAA receptor subunits258. 
Figure 5.2. 
Pentameric Structure 
of the GABAA
Receptor9,10. 
 
GABAA receptor compositional heterogeneity has been shown to mediate 
different electrophysiological and pharmacological properties of GABAA receptors259,260. 
This may explain why alterations in GABAAR function have been associated with the 
pathology of several neurological and psychiatric illnesses such as epilepsy, anxiety, 
Alzheimer’s disease and schizophrenia259,261-265.  Structural heterogeneity of mammalian 
GABAA receptors is attributed to the existence of nineteen known subunit variants 
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grouped according to seven classes of subunits (alpha1-6, beta1-3, gamma1-3, delta, 
epsilon, phi, pi, and rho1-3)250,266,267, giving rise to a large number of possible subunit 
combinations and providing a molecular mechanism for regulating GABAA receptor 
function259,268-272. Indeed, subunit composition determines not only GABAA receptor 
pharmacology, channel properties236,245,257,273,274 and modulation by endogenous 
ligands275 or second messenger systems276,277, but also cell surface localization227,278 
and intracellular targeting to different locations271,279, which is important because 
functionally distinct neurons appear to express more than one GABAA receptor 
subtype224,258,260,280. Therefore, it has been suggested that differential assembly and 
subunit stability, subcellular compartmentalization, and temporal regulation may provide 
mechanisms by which GABAA receptor composition is modulated10. Evidence for spatial 
regulation comes from in situ hybridization and immunohistochemical studies which 
have revealed that some GABAA receptor subunits are confined to defined locations 
(e.g., alpha5 in hippocampal pyramidal cells, alpha6 in cerebellar granule cells, rho1 in 
retinal bipolar cells, and alpha4 in hippocampal dentate gyrus cells)224,259. Membrane 
insertion or internalization of GABAA receptors are a mechanism by which GABAA 
receptor stability at neuronal synapses may be regulated281. Furthermore, GABAA 
receptor complexity is gained due to alternative splicing of specific subunit mRNA 
transcripts. Each subunit has its own gene259,282 and the existence of multiple 
promoters224, which are reportedly involved in mediating developmental or tissue-
specific expression283-286, further contributes to the regulatory diversity of the GABAA 
receptor. 
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CHAPTER 6 - Aging and Central Autonomic Regulation of 
Blood Pressure 
 
Advancing age is associated with abnormalities in autonomic function resulting in 
impaired SND regulation under basal conditions and in response to stress33. The 
consensus view is that the sympathetic dysregulation that occurs with advancing age is 
characterized by regionally selective, non-uniform elevations in basal sympathetic nerve 
activity5,8,87,287-306. For example, the sympathoexcitatory state in the aged is primarily 
attributed to increases in basal sympathetic outflow to the heart, liver-gut circulation and 
skeletal muscle305,307,308 but not to the kidney, adrenal medulla291 or skin309.  
 
Plasma norepinephrine (NE) levels have been routinely used as a determinant of 
systemic sympathetic activation in experimental subjects. Alterations in plasma NE 
concentrations have been reported in aged 
individuals at rest310-313 (figure 6.1), under acute 
stress (e.g., mental, exercise)93, or in disease states 
(e.g., chronic heart failure)314,315. Esler and 
coworkers reported that mean plasma NE levels in 
healthy men between the ages of 60 and 75 were 
66% higher compared to healthy, younger control subjects291. Cardiac NE spillover was 
reportedly 2- to 3-fold higher and 53% higher in the aged during mental stress and 
dynamic exercise, respectively, compared to young male subjects93. Collectively, these 
Figure 6.1. Plasma Norepinephrine
Levels Increase With Advancing
Age in Humans5. *p<0.05. 
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studies suggest higher levels of sympathetic outflow in aged experimental human 
subjects. 
 
Potential Mechanisms Contributing to Age-dependent Sympathetic Activation 
NE Clearance. It has been suggested that elevations in NE spillover are due to 
age-related increases in the release of NE from sympathetic postganglionic nerve fibers 
innervating the heart, liver-gut circulation and skeletal muscle93,305; however, reductions 
in NE clearance may also contribute to the total NE spillover observed in the aged314,315. 
Indeed, Esler and others291 found that while aged men at rest had 66% higher mean 
plasma NE levels compared to their young counterparts, this elevation was correlated 
with a 22% reduction in plasma NE clearance, suggesting that NE release and uptake 
are augmented with advancing age. 
  
Impaired Baroreflex Buffering. It is also possible that the progressive sympathetic 
activation that occurs with age may be attributed to loss of baroreflex sensitivity and 
may contribute to altered sympathetic support of arterial pressure. Independent of 
clinical disease, impaired baroreceptor reflex sensitivity is commonly associated with 
advancing age in healthy humans293,305 and in experimental animal models288,292,316,317. 
Physiological consequences of depressed baroreflex responsiveness that have been 
reported in aged humans and rats include impaired heart rate287,316,318,319 and SND 
responses to baroreceptor activation288,292,316,317. For example, Irigoyen and coworkers 
reported that renal SND responses were attenuated in aged rats when baroreflex-
mediated inhibition of efferent SND was withdrawn316. Similarly, Hajduczok and others 
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demonstrated reductions in baroreflex-mediated inhibition of renal SND in senescent 
compared to mature, adult beagles, confirming that sensitivity to the baroreflex is 
altered with advanced age301. In order to demonstrate age-related alterations in 
autonomic support of arterial blood pressure in humans, Jones and coworkers 
administered trimethaphan to healthy young (24 ± 1 yrs) 
and aged (65 ± 2 yrs) men in order to produce short term 
blockade of ganglionic neural transmission and effectively 
remove baroreflex influences8. Although systolic (SAP), 
diastolic (DAP) and mean arterial pressure (MAP; figure 
6.2) were reduced in both young and aged subjects in 
response to ganglionic blockade, all three parameters were 
reduced to a greater extent in the aged individuals examined, suggesting that at rest 
aged individuals have higher levels of sympathetic nerve outflow compared to young. In 
a similar study Jones and others reported that the depressor responses observed in the 
aged following ganglionic blockade was primarily due to failure to increase heart rate as 
would be expected following removal of baroreflex-mediated inhibition of sympathetic 
vasomotor outflow, demonstrating that substantial reductions in baroreflex buffering 
occurs with advancing age8. 
Figure 6.2. Altered 
Cardiovascular Support With
Advanced Age8. 
  
Similar findings have been derived from studies using experimental animals to 
determine whether sympathetic support of MAP is altered with aging. Recently we have 
completed experiments whereby MAP and SND responses to ganglionic blockade in 
young and middle-aged Fischer 344 (F344) rats were determined. Prior to trimethaphan 
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administration the level of MAP did not differ between young (130 ± 2 mmHg) and 
middle-aged (133 ± 5 mmHg) F344 rats. Although ganglionic blockade with 
trimethaphan effectively eliminated renal and splenic SND and reduced MAP in both 
young and middle-aged rats, depressor responses were significantly greater in the 
middle-aged (86±3 mmHg) compared to young 
F344 rats (67 ± 4 mmHg) (figure 6.3). 
Trimethaphan-mediated reductions in MAP 
were also observed in aged F344 rats (124 ± 
15 mmHg control; 43 ± 3 mmHg post-
blockade), demonstrating that similar to 
humans, outflow to sympathetic postganglionic 
neurons is elevated with advancing age in the 
rat. Therefore, these findings indicate that in 
both humans and animal subjects sympathetic 
support of MAP is altered with advancing age, 
a finding that is supported by evidence from 
experimental animal models in which a 
relationship between age-associated increases 
in SND and impairments in baroreflex-
mediated inhibition of SND have been established288. 
Figure 6.3. Altered Autonomic Support of
Arterial Pressure With Advancing Age.
Ganglionic blockade eliminated renal and
splenic postganglionic nerve activity in
both young and middle-aged (MA) F344
rats (top); however, significantly greater
reductions in MAP were observed in MA
compared to young F344 rats following
trimethaphan administration (bottom). 
This suggests that at rest MA rats exhibit
higher levels of tonic sympathetic activity
compared to young rats (R. Fels,
unpublished data).  * p<0.05. 
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Vascular Insensitivity.  Studies in which the effect of age on baroreflex buffering 
was examined determined that age-related impairment in baroreflex responsiveness 
was due in part, to reduced vascular adrenergic sensitivity320-322. Indeed, 
vasoconstriction and therefore, MAP responses to phenylephrine administration 
following ganglionic blockade are attenuated in 65 year old men; a response mediated 
by reductions in vascular epithelium alpha1 adrenergic receptor sensitivity to 
phenylephrine293 (figure 6.4). These results indicate that markedly reduced vascular 
alpha1 adrenergic receptor responsiveness contributes to impairment of baroreflex 
buffering in the aged. 
 
 
 
 
 
Figure 6.4. Reduced Vascular 
Sensitivity to an Alpha-
adrenergic Receptor Agonist 
With Aging8. Increases in MAP 
responses to phenylephrine 
during ganglionic blockade 
were significantly reduced in 
men 65 years of age compared 
to those 25 years of age. 
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Significance 
Central mechanisms underlying age-associated changes in SND regulation are 
not well understood. Many pathophysiological diseases including type II diabetes75-78, 
hypertension87, congestive heart failure93-96, insulin resistance75,82,97, and obesity88-91 are 
associated with sympathetic dysfunction. Of particular interest is that the prevalence of 
these disease states is known to increase with advancing age. This is of critical 
importance because it is estimated that globally, the number of aged persons between 
60 and 80 years or over will increase eight-fold by 205042. Therefore, understanding the 
cellular and molecular mechanisms by which normal aging affects centrally-regulated 
SND is critical for understanding the relationships between the onset of critical disease 
and normal age-related changes in sympathetic neural function.  
 
It is currently unclear how aging affects central mechanisms regulating efferent 
SND, although it is well established that progressive increases in sympathetic activation 
occur with advancing age independent of clinical disease291. The RVLM plays a critical 
role in regulating sympathetic nerve outflow and is considered the single most important 
source of tonic excitatory drive to sympathetic nerves involved in the maintenance of 
arterial pressure4. Both excitatory and inhibitory neural inputs serve as the predominate 
mechanism by which RVLM neural activity is tightly modulated128,129,140,143; therefore we 
suspect that the increase in sympathetic activation that is commonly observed in the 
aged is attributed to withdrawal of GABAergic inhibitory neural input to the RVLM. 
Because GABAA receptors are highly involved in mediating the inhibitory influence of 
GABAergic tone in the RVLM4,172,177,205, the primary objective of the current study was 
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to examine whether aging differentially alters the RVLM GABAergic neurotransmitter 
gene expression profile in a rodent model of aging.  
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CHAPTER 7 - The Fischer 344 Rat as an Animal Model of 
Chronological and Biological Aging 
 
The current understanding of physiological aging in mammals is based in large 
part on studies that have used young (5-6 mo. old), middle-aged (14-16 mo. old), and 
aged (24-25 mo. old) rats to examine the process of chronological aging323. Recently, 
studies have suggested that biological age rather than, or in addition to, chronological 
age may be a useful tool for evaluating the effect of age on physiological function323-325. 
Advanced stages of chronological and biological aging are associated with spontaneous 
reductions in body weight and food intake325-327, collectively termed the “anorexia of 
aging”326,328 or “failure to thrive”329,330. The development of anorexia occurs without 
definitive cause in healthy elderly individuals331 or experimental rodent models of 
aging326,332,333, and has been suggested to be a prelude to natural death328,330,334,335.  
 
Towards the end of their natural life spans, Fischer 344 (F344) rats exhibit 
reductions in food intake324-326,336,337, body weight regulation323,337,338, 
thermoregulation323,337,339, and circadian rhythmicity323,337,339. Independent of disease, 
death occurs within an average of 3 weeks326; therefore, these deleterious events have 
been previously used as markers to define senescence324-326,334,335,340,341. Rats that 
display a failure to thrive and are rapidly progressing towards death are considered 
senescent323-325,334,335,341. However, similar to aging humans, the transition to 
senescence and subsequent progression towards death is highly variable between 
aged F344 rats. For example, McDonald and coworkers reported that the age at which 
 33
senescence occurs in F344 rats ranges between 24 and 31 mo. of age323-325 and while 
all animals included in this particular study exhibited spontaneous rapid loss of body 
weight near the end of their life, the pattern of weight loss also varied323-325. In a 
separate study conducted by Coppola and others338, F344 rats generally began 
spontaneous weight loss at 29 mo. of age, with an average duration of senescence 
before death lasting 16 ± 7 days. Therefore, biological rather than, or in addition to 
chronological guidelines are necessary for defining senescence. As a result, a 
descriptive definition of senescence was proposed by McDonald337, describing a 
senescent rat as one that has lost an average of 10% total body weight over a period of 
7-10 days338. 
 
The use of laboratory rodents as a model of human aging is well established. 
Importantly, it has been suggested that the underlying mechanisms mediating brain 
aging are similar among most mammalian species, including humans and rats342. A 
number of rodent aging models exist and have been widely used in studies involving 
aging; however, Fisher 344 rats have been used in the majority of studies designed to 
investigate the effects of aging on central regulation of SND using direct nerve 
recordings. Studies conducted by our laboratory revealed the presence of synchronized 
cardiac-related SND bursts in young (3-5 mo. old), middle-aged (12 mo. old), and 
weight-stable aged (24-25 mo. old) F344 rats. Direct nerve recordings of renal, adrenal, 
and splenic SND from a 24-mo. old (aged) F344 rat are shown in figure 7.1. Notably, 
muscle sympathetic nerve recordings from aged humans exhibit similar synchronized, 
cardiac-locked bursting patterns (figure 7.1), thereby validating the appropriateness of 
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the F344 rat as an experimental model to examine age-related alterations in SND 
regulation.  
 
 
 
 
 
 
 
 Figure 7.1. Cardiac-related Sympathetic Nerve
Discharge Bursts in an Aged F344 Rat and an Aged
Human. (R. Fels, unpublished data). 
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CHAPTER 8 - Materials and Methods 
 
Description of Experimental Age Groups. Age-dependent alterations in RVLM 
constitutive gene expression profiles were examined in five healthy adult young (3-5 
month old), four middle-aged (12 month old), and six aged (24-32 month old) male 
Fischer 344 (F344) rats obtained from the National Institutes of Health on Aging colony 
maintained by Harlan Sprague Dawley Laboratories. Twenty-four to thirty-two month old 
rats were further classified according to body weight. F344 rats demonstrating stable 
body weights were designated “presenescent” rats (n=3) while those exhibiting 
spontaneous and rapid weight loss were defined as “senescent” (n=3), following 
guidelines set by McDonald and Coppola337 as previously described.   
 
Animal Housing. Rats were housed in the animal care unit in Coles Hall in the College 
of Veterinary Medicine at Kansas State University. Veterinary care and animal 
husbandry procedures were administered by the veterinary and Animal Resource 
Facility staff at Kansas State University. All rats were housed in ventilated racks 
(Allentown) receiving 27 air exchanges per hour in 10.5 x 19 x 11-in. cages filled with 
Tek-fresh (Harlan) bedding and a paper towel for enrichment. All rats had free access to 
rack suspended standard rat chow (Laboratory Rodent Diet 5001) and water, and were 
maintained on a 12:12-hr. light-dark cycle. This study was approved by Kansas State 
University Institutional Animal Care and Use Committee and was completed in 
accordance with the guidelines for the care and use of laboratory animals of the 
National Institutes of Health and the American Physiological Society.  
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Health Monitoring of Aged and Senescent F344 Rats. The Fischer 344 rat is a 
commonly used experimental model of aging343. However, a high incidence of age-
related pathology (e.g., testicular and pituitary adenomas, adrenal capsular fibrosis, and 
renal disease) has been associated with this rodent strain326. Of particular relevance to 
F344 health is the relatively high incidence of leukemia with advancing age344-346. 
Reportedly, 30 to 50% of aging F344 rats allowed to live a normal life span die from the 
effects of leukemia344,346, which represents the leading natural cause of death in this 
strain347-352. Clinical indicators of leukemia include decreased redness of the eyes 
(anemia), spontaneous and substantial reductions in body weight, abdominal 
distension, weakness345 and splenomegaly345,346,353. However, hematological 
examination with a specific focus on elevated white blood cell counts and a blood smear 
test345,346 are required for confirmation. Therefore, careful health monitoring is required 
to distinguish healthy aged animals from unhealthy or diseased aged animals in order to 
reduce confounding etiological influences.  
 
The health status of all 24-32 month old (aged) F344 rats was routinely 
monitored and recorded using select parameters that included body weight, food and 
water intake, and behavior profiles (alertness and activity, grooming and coat condition, 
and posture). Additionally, all aged animals were photographed upon arrival from the 
vendor and on the day of sacrifice in order to document any potential age-dependent 
changes in appearance. All aged rats were monitored for weight loss and overall health 
status at least once a week, because terminal weight loss is considered a marker for 
senescence323-325,340. Cages containing animals which exhibited weight loss of at least 
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3-5% body weight (e.g., transitioning into senescence) were immediately removed from 
the ventilated rack and placed on a cart within the same room to allow for more detailed 
observation. At this time moist standard rat chow was offered ad libitum in addition to 
free access of rack suspended dry rat chow. Due to the variability in the length of 
transition into full senescence (i.e., loss of at least 10% body weight338); transitional rats 
were monitored for weight loss and overall health status at least 2-3 times per week. 
During periods of observable rapid progression towards death, transitional animals were 
monitored on a daily basis and/or several times throughout the day when necessary. 
Prior to sacrifice, body condition and hydration scores were determined by the same 
attending veterinarian in order to prevent inter-individual variability in scoring. Spleen 
and brain morphology were evaluated postmortem by members of our laboratory and 
hematological analysis (CBC, serum chemistry) was performed by the Diagnostic 
Laboratory located at Kansas State University, College of Veterinary Medicine in order 
to identify leukemic rats or detect potential organ dysfunction. When necessary, 
necropsies and histopathology were performed by veterinary pathologists at Kansas 
State University. Collectively, this information was used to exclude aged animals that 
exhibited one of more of the following: dehydration, leukemia, observable brain tumors, 
significantly altered serum chemistry, and/or blood count profiles. Importantly, we have 
successfully used these criteria to detect and exclude a number of 24-32 mo. old F344 
rats from our gene expression profiling studies, thereby increasing the likelihood that 
our findings are attributed to the aging process and not a disease state.  
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RVLM Tissue Micropunch. Animals were anesthetized with 5% isofluorane and 
decapitated by guillotine (Braintree Scientific). At this time, blood was collected and 
immediately submitted for hematological analysis. Brains were quickly removed, snap 
frozen in liquid nitrogen-cooled isopentane and stored at -80°C until further processing. 
RVLM tissue was isolated according to procedures established by Durgam and Mifflin354 
and Li and others355.  Briefly, brains were gently mounted in a cooled rodent brain slicer 
(Braintree Scientific) using Tissue-Tek (Sakura) and cut into 500 μm coronal sections 
using a razor blade. Brain slices were subsequently placed onto chilled microscope 
slides and anatomical landmarks of the RVLM were identified as described by Paxinos 
and Watson2 (figure 8.1) using a surgical microscope. Bilateral RVLM tissue, located at 
approximately -11.8 mm Bregma, was isolated using a sterile blunt-end 20 gauge 
needle and immediately placed in Trizol reagent (Sigma) in preparation for total RNA 
isolation.  
 
 
 
 
 
 
 
 
 
Figure 8.1. Anatomical Landmarks Used for RVLM Micropunching2. 
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RNA Isolation and Reverse Transcription. Total RNA was isolated following standard 
protocol. RVLM tissue micropunches were homogenized in TRI Reagent (Sigma) using 
a battery operated hand-held pestle and total RNA purity and concentration were 
determined using a Nanodrop 1000 (Nanodrop). Potential genomic DNA contamination 
was removed and RVLM total RNA samples (1-2 μg) were reverse-transcribed using 
QuantiTect Reverse Transcription kit (Qiagen). Reverse transcription reactions were 
carried out at 42°C for 30 min. Resultant cDNA was used for individual and array-based 
SYBR Green® real-time PCR applications.  
 
Array-based SYBR® Green Real Time PCR. Constitutive gene expression profiling was 
completed using the rat Neurotransmitter Receptors and Regulators RT2 Profiler™ PCR 
array (#APRN-060A) commercially available from Superarray. Complementary DNA 
was used for real-time PCR based pathway-focused gene expression profiling. The 
expression of 84 genes involved in regulating the biological processes of 
neurotransmitter biosynthesis, uptake, transport, and signaling through neurotransmitter 
receptors, including receptors specific for GABA, acetylcholine, benzodiazepine, 
dopamine, glutamate, serotonin, somatostatin, and neuropeptides were included on this 
array in addition to five well-established housekeeping genes and three controls. 
Twenty-microliter reverse transcription reactions containing 1μg RVLM totRNA were 
mixed with an experimental cocktail containing RT2 SYBR® green/fluorescein qPCR 
master mix (Superarray) and molecular grade water. Fluorescein was included as a 
reference dye for the purpose of normalizing the optics of the Bio-Rad iCycler. Twenty-
five microliters of this cocktail were added to each well of the 96-well array so that the 
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final concentration of initial RVLM totRNA loaded per well was 9.0 ng. Real-time PCR 
reactions were performed under the following conditions on a Bio-Rad iCycler: 10 min at 
95°C (cycle 1) followed by 40 cycles of 1 min at 60°C. SYBR® green fluorescence was 
detected and recorded from every well during the annealing step of each cycle. The 
efficacy of each reaction was verified by the running of a melt curve from 60°C to 95°C, 
increasing at 0.2°C/second. In addition, prior to commercial availability, Superarray had 
established that the RT2 qPCR array had amplification efficiencies greater than 90% 
with amplicons ranging from 100-250 bp in size. Array-based real-time PCR results 
were analyzed using an Excel data analysis template available from Superarray. This 
format allows for the automatic calculation and interpretation of sample and control 
wells following the addition of an array-specific gene list and the threshold cycle data 
generated from the Bio-Rad iCycler. Data analysis was based on the comparative Ct 
method (2-ΔΔCt) with normalization of the raw data to housekeeping genes that were 
included in the array. Expression levels were calculated as fold change relative to the 
gene expression of control samples. The threshold cycle (Ct) value for each gene was 
defined as the PCR cycle at which emitted fluorescence rose above a background level 
of fluorescence and was set at 40.4 with cycles 2-17 selected as baseline cycles using 
software provided with the Bio-Rad iCycler.  
 
Data and Statistical Analysis.  Results were compared between groups using Student’s 
t-test. The overall level of statistical significance was set at p < 0.05.  
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CHAPTER 9 - Experiments and Data 
 
Independent of clinical disease, SND is progressively activated with advancing 
age5,8,87,287,288. Virtually nothing is known about the effect of age on central neural 
mechanisms regulating efferent SND, although it is possible that the sympathetic 
activation that occurs with aging is attributed to alterations in brainstem 
neurotransmitters. Multiple supraspinal neural circuits are critically involved in the 
regulation of SND4,6,15,16,18; however, the RVLM serves as the final common pathway for 
the integration of centrally regulated pressor responses and efferent SND4,12,18,129. 
Excitatory neural inputs to the RVLM are normally balanced by powerful GABAergic 
inhibitory tone mediated in large part by GABAA receptors128,129,140-143,145,356. Therefore, 
the RVLM is a candidate neural substrate for investigating central molecular 
mechanisms regulating sympathetic outflow. In the present study we hypothesized 
that within the RVLM GABAergic inhibition of SND is withdrawn during aging, 
thereby shifting the balance of tonic influence towards enhanced RVLM excitation 
and potentially providing the mechanistic basis for age-related alterations in arterial 
pressure support. Importantly, nothing is known about the effect of advancing age 
on the role of RVLM neural circuits in SND regulation; therefore we expect that 
testing of our hypothesis will provide insight into the RVLM GABAergic neurotransmitter 
system and further, central neural mechanisms regulating SND during advancing age.  
 
Much of our current understanding about the diversity of central 
neurotransmitters has come from detailed cellular and molecular biological studies 
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using the rat357. Although F344, Brown Norway, Brown Norway x F344, and F344 x 
Brown Norway rodent strains have been widely used in studies involving aging, 
traditionally the preferred model of rodent aging and sympathetic nerve regulation is the 
F344 rat. Therefore, the molecular biological experiments presented hereafter were 
designed to examine potential age-related differences in constitutive GABAA receptor 
gene expression in the RVLM of F344 rats using an array-based real-time PCR 
approach (figure 9.1). Such an 
approach allowed for the 
simultaneous and comprehensive 
screening of 19 GABAA-related 
genes and 65 genes related to 
other neurotransmitters, of which 
we focused on the muscarinic, 
nicotinic and dopaminergic receptor 
systems due to their reported 
involvement in GABAA receptor 
modulation. It is expected that our 
findings will reveal potential RVLM 
neurotransmitter mechanisms that may be involved in mediating age-dependent 
alterations in the regulation of efferent SND in the F344 rat.  
 
 
 
Figure 9.1. Rationale and Experimental Approach. We 
hypothesized that elevated SND with advanced aged
may be attributed to withdrawal of GABAergic tone
within the RVLM (text box with dotted lines). An array-
based real-time PCR approach was used to determine
the effects of aging on the expression of genes related
to GABAergic, cholinergic and dopaminergic receptor
systems.  
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Selection of F344 Rats for Real-time PCR Experiments 
Five adult young (3-5 month old), four middle-aged (12 month old), and six aged 
(24-32 month old) F344 rats were selected to evaluate the effect of age on constitutive 
RVLM neurotransmitter system gene expression. In order to examine the effects of both 
chronological and biological age of 24-32 month old rats, aged rats were further 
classified as previously described, resulting in three presenescent and three senescent 
F344 rats available for real-time PCR analysis. Importantly, all rats were healthy and 
there were no indications of leukemia in any of the aged rats, thereby eliminating 
confounding factors that could potentially lead to misinterpretation of the data.  
 
Real-time PCR RVLM Gene Expression Profiling: Selection of an Appropriate 
Housekeeping Gene 
The use of real-time PCR to identify changes in gene expression has gained 
increasing popularity in aging research358-360. Relative quantification of gene expression 
data generated from real-time PCR experiments requires the identification of a 
housekeeping (HK) gene by which to normalize the expression of target genes361,362 in 
order to eliminate potential experimental influences including differences in the amount 
and quality of starting material, differences in RNA preparation and efficiencies of 
reverse-transcription reactions362. According to Touchberry and coworkers, 
“housekeeping genes are essential endogenous regulatory genes that are involved in 
various processes in the cell, such as metabolism, cell structure, gene transcription, and 
homeostasis, and are therefore constitutively expressed”363. Ideally, the expression of 
HK genes should not be affected by experimental modulation361, age363,364, or cell and 
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tissue type362; therefore these criteria are commonly used to determine the 
appropriateness of candidate HK genes in real-time PCR analysis applications. 
However, selection of HK genes for use in real-time PCR has proved difficult as 
variations in HK gene expression have been reported for different tissue types362,365-367 
and several studies have reported changes in HK gene expression following a variety of 
experimental conditions including hypoxia368, exercise369,370, diet supplementation371 
and aging363,364, demonstrating that it is highly unlikely that a “universal” HK gene exists 
that is appropriate for use under all experimental conditions372,373.  
 
The difficulty in selecting valid HK genes for aging studies was demonstrated by 
Chen and others, who reported large variations in the expression of five commonly used 
HK genes including, beta-actin (Actb), glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), ubiquitin C (UBC), hypoxanthine phosphoribosyl-transferase (Hprt) and 
cyclophilin A (CYPa). The expression of Actb, GAPDH, UBC, CYPa were found to be so 
variably expressed between young and aged rat livers, that only Hprt was determined to 
have the most stable expression suitable for accurate normalization364. A similar study 
conducted by Touchberry and coworkers examined the appropriateness of GAPDH, β2-
microglobulin (β2M) and RNA polymerase 2a (polR2a) as HK genes in skeletal muscle 
from young and elderly human subjects and identified only GAPDH as the HK gene that 
demonstrated the most stable expression with age. Although the expression of β2M was 
found to be significantly different between young and elderly age groups, it exhibited low 
variability within each age group, further demonstrating the difficulties of choosing valid 
HK genes for use in gene expression studies using aged subjects and different tissue 
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types363. To the author’s knowledge, at the present time, the reports by Chen and 
Touchberry are the only ones that have comprehensively investigated and identified 
appropriate HK genes to use specifically in aging research363,364; however, reports that 
have extensively evaluated HK gene expression in the aging brain do not exist. 
Relatively few RVLM neurotransmitter gene expression studies using real-time PCR 
have been completed374-377, none of which included aged experimental subjects. 
Therefore, at the present time there are no established guidelines for which HK genes 
are appropriate for investigating age-related changes in gene expression within the 
RVLM, as any differences in HK gene expression between age groups would make it 
difficult to make age-dependent comparisons with confidence and may inadvertently 
skew data such that differences are identified, when actually none exist363. Indeed, 
Chen and coworkers reported that when normalizing the expression of Cu/Zn-
superoxide dismutase using a HK gene that was significantly decreased in aged rats 
(UBC), a significant difference in Cu/Zn-superoxide dismutase expression was detected 
between young and aged rat livers. However, use of Hprt, a HK gene stably expressed 
in the liver with age, for normalization resulted in no statistically significant differences in 
Cu/Zn-superoxide dismutase expression between age groups. Furthermore, when using 
UBC to normalize catalase levels in the livers of young and aged rats, it was determined 
that aged rats expressed 31.20% less catalase than young rats; however, when 
catalase expression was normalized to Hprt, aged rats were found to express 57.73% 
less catalase363,364. This situation clearly highlights the necessity for a stably expressed 
HK gene for use in studies using aged experimental subjects, as normalization of real-
time PCR data with an inappropriate HK gene can result in misinterpretation of data. 
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 Beta-actin is a well established housekeeping gene361,366,378,379 and has been 
used in a number of gene expression studies using a variety of tissues and cell types 
including the spleen116, brain367,380, skeletal muscle366, and liver367, demonstrating the 
stability of this gene product across a number of tissues; an important characteristic of a 
suitable HK gene. In a recent study evaluating the expression of thirteen different HK 
genes in sixteen different tissues including the brain, spleen and heart, actin was shown 
to be highly expressed in all tissues examined362. However, none of the studies 
described above 
investigated the effect of 
age on brain actin gene 
expression, although 
Slagboom and others 
reported that age did not 
affect beta-actin mRNA 
expression in the brains of 
female inbred rats ranging 
from 6 and 24-months to 36 
months of age367. While the 
work of Slagboom did not  
Figure 9.2. Rationale and Experimental Approach for
Determining the Appropriateness of Beta-actin as a HK Gene 
in F344 Rats. Beta-actin has been used as a HK gene in a
number of studies involving a variety of tissues and
experimental treatments. Our experimental approach for 
confirming beta-actin as a suitable HK gene for use in aging
studies involved the examination of its expression in the spleen
and regionally distinct parts of the brain in F344 rats. Sprague
Dawley rats were included in order to determine whether actin 
expression is influenced by stress.   
 
comprehensively examine the expression of a variety of HK genes in the aged rat brain, 
it does suggest that beta-actin may be a potential candidate for use in real-time PCR 
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experiments designed to identify age-related changes in gene expression in the brains 
of F344 rats (figure 9.2).  
 
Establishing Beta-actin as an Appropriate HK Gene for Use in Real-time PCR 
Experiments Using Aged Subjects  
The 2-ΔΔCt method is commonly used to calculate relative changes in gene 
expression determined from real-time PCR experiments; however, in order for such 
calculations to be accurate, the amplification efficiencies of target and housekeeping  
 
 
 
 
 
 
genes must be equivalent361. Our laboratory determined the annealing efficiencies of 
primers specific for beta-actin as well as select target genes using commercially 
Figure 9.3. Amplification Efficiency Curves. The amplification efficiency of primers 
specific for beta-actin (A) and GABAA receptor subunits alpha1 (B), beta3 (C) and 
gamma2 (D) was determined using a randomly selected F344 rat cortical brain
sample. 
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available primers (Superarray) and a randomly chosen cortical brain cDNA sample from 
a presenescent F344 rat. Standard curves were generated using relative cDNA 
concentrations and threshold cycle (Ct) values generated from SYBR® Green real-time 
PCR. Figure 9.3 shows representative efficiency curves for beta-actin (A) and GABAA 
receptor subunits alpha1 (B), beta3 (C) and gamma2 (D). The linear correlation 
coefficient (R2) of all genes examined was highly similar, with R2 values ranging from 
0.997-0.999, suggesting that potential identification of relative changes in the 
expression of specific genes of interest using Ct values generated from real-time PCR 
experiments would be accurate when normalized to beta-actin. 
 
Because beta-actin amplification efficiency was found to be highly similar to 
those of select GABAA receptor subunits, we examined whether beta-actin expression 
was altered by aging in the spleens of young (3-5 month old) and weight stable 
presenescent (24-32 month old) F344 rats under basal conditions. We selected the 
spleen because beta-actin is highly expressed in this tissue and it has been used in 
studies involving Sprague Dawley (SD) rats previously published by our 
Figure 9.4. Beta-actin is Stably Expressed in the Spleen of F344 and SD  Rats. The influence of 
age (A) and stress (B) do not markedly affect splenic actin gene expression. F344 rats were 
used to determine whether aging affects splenic beta-actin gene expression (A). Effects of 
experimental modulation on splenic beta-actin gene expression were investigated using SD rats 
(B, C).  
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laboratory116,117. As figure 9.4(A) demonstrates, the average Ct value of splenic beta-
actin did not differ between young (17.71 ± 0.50; n=4) and presenescent (aged; 18.08 ± 
0.29; n=4) F344 rats.  Similarly, beta-actin expression was found to be consistent in the 
spleens of young SD rats exposed to short bouts of heat stress (16.75 ± 0.10; n=4) and 
in untreated controls (sham; 16.90 ± 0.23; n=2) (figure 9.4B). Splenic beta-actin 
expression was also unaffected following the administration of saline (22.55 ± 1.07; 
n=4) or the GABAA receptor antagonist bicuculline (BIC) into the RVLM in splenic nerve 
intact young SD rats (23.15 ± 1.20; n=4) (figure 9.4C). These data suggest that beta-
actin is highly expressed in the spleen and is relatively unaffected by potential 
influences of age (young, presenescent) and experimental modulation (heat, saline or 
BIC RVLM), thereby meeting several criteria for what is considered an acceptable HK 
gene to be used for normalization purposes.  
 
 
 
 
 
 
 Figure 9.5. Beta-actin Gene Expression is Stable in the Spleen. Real-time 
PCR analysis indicated that aging does not affect beta-actin gene expression 
in the spleen of F344 rats. Beta-actin expression was consistently expressed 
in the spleen of Sprague Dawley rats with heart failure and following RVLM 
microinjection of bicuculine and splenic denervation. 
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Our real-time PCR studies using the spleens of F344 and SD rats confirmed that 
beta-actin is an acceptable HK gene in studies involving different ages and 
experimental manipulation thereby meeting the criteria of 1) abundant expression and 
2) expression is unaltered with treatment (here, age may be considered a treatment, 
(figure 9.5).  Therefore, we completed experiments to determine whether beta-actin was 
an appropriate HK gene in tissues from distinct regions of the brain. Specifically, we 
examined beta-actin gene expression in the cortex, forebrain (paraventricular nucleus of 
the hypothalamus; PVN) and brainstem (RVLM) to establish beta-actin as an HK gene 
for use in real-time PCR studies designed to address the primary objective of the 
current study; whether aging affects neurotransmitter gene expression in the RVLM of 
F344 rats.   
 
Individual real-time PCR analysis of cortical tissue micropunches revealed 
average actin Ct values of  19.73 ± 0.62, 19.01 ± 0.11, 20.28 ± 0.53 and 19.14 ± 0.13 
from adult young (3-5 month old; n=4), middle-aged (12 month old; n=4), weight stable 
Figure 9.6. Beta-actin is Stably Expressed in the Cortex of the
Rat Brain. Beta-actin expression did not differ between young,
middle-aged, presenescent and senescent F344 rats (A).
Sprague Dawley rats were included in the analysis to determine
whether stress affected cortical beta-actin expression (B). Stress 
did not affect actin expression. 
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presenescent (24-32 month old; n=5) and senescent (24-32 month old; n=5) F344 rats, 
respectively (figure 9.6A). This suggested that similar to the spleens of F344 rats, beta-
actin gene expression is not affected by advancing age in cortical brain tissue. Similarly, 
no difference in beta-actin expression was observed in cortical tissue micropunches 
from young sham operated (24.87 ± 0.47; n=3) and young SD rats suffering from mild 
(25.73 ± 1.29; n=3) or severe (25.80 ± 1.98; n=3) forms of heart failure (figure 9.6B), 
indicating that age or stress-related (heart failure) influences do not markedly affect 
cortical actin gene expression.  
 
Importantly, our studies indicated that cortical beta-actin gene expression was 
not markedly influenced by stress in SD rats and that it was consistently expressed in 
the cortex of young, middle-aged, presenscent and senescent F344 rats, suggesting its 
suitability as a HK gene for normalization purposes in aging studies using F344 brain 
tissue. Therefore, we examined potential age-associated changes in the expression of 
beta-actin in more discrete regions of the brain including the PVN and RVLM, two 
autonomic nuclei located in the forebrain and brainstem, respectively. Individual real-
time PCR analysis of F344 paraventricular nucleus of the hypothalamus (PVN) beta-
Figure 9.7. Beta-actin Gene Expression in the PVN is Not Influenced 
By Age or Heart Failure. Beta-actin expression did not differ between 
young, middle-aged, presenescent and senescent F344 rats (A) or in
SD rats suffering from heart failure (B). 
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actin gene expression revealed similarities in Ct values among young (21.58 ± 0.39; 
n=4), middle-aged (21.25 ± 0.40; n=4), presenescent (21.19 ± 0.27; n=5) and senescent 
(21.24 ± 0.31; n=5) age groups (figure 9.7A), confirming previous findings in the spleen 
and cortex of F344 rats. Importantly, no differences in PVN actin expression were 
observed for SD rats that were sham operated (22.6 ± 0.17; n=3) or suffering from heart 
failure (21.91 ± 0.36, mild n=3; 22.58 ± 0.07, severe n=3) (figure 9.7B), providing strong 
evidence that neither age or stress (heart failure) influence beta-actin expression in the 
rodent PVN.  
 
Consistent beta-actin expression in the spleen, cortex and PVN of F344 and SD 
rats regardless of age or stressor lead us to hypothesize that aging and stress would 
not affect beta-actin expression in the RVLM. However, expression studies of RVLM 
tissue from young (n=5), middle-aged (n=4), presenescent (n=3) and senescent (n=3) 
F344 rats using real-time PCR provided unexpected results. In contrast to what was 
observed in the spleen, cortex and PVN, beta-actin was not stably expressed in the 
Figure 9.8. Aging Affects Beta-actin (Actb) Gene Expression in the RVLM. 
Presenescent and senescent F344 rats expressed higher levels of RVLM beta-
actin than young and middle-aged F344 rats (A). In contrast, beta-actin 
expression in the RVLM was not influenced by heart failure in SD rats (B), 
demonstrating the changes that we observed were specific to aging.  
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RVLM during aging in the F344 rat although it was unaffected by heart failure in SD rats 
(figure 9.8). Age-dependent beta-actin expression patterns were consistently observed 
between young and middle-aged F344 rats, and presenscent and senescent F344 rats. 
Young and middle-aged rats exhibited average RVLM Ct values of 24.50 ± 1.08 and 
24.35 ± 1.55 while presenescent and senescent rats exhibited average Ct values of 
21.23 ± 0.64 and 22.23 ± 0.35, respectively (figure 9.8A), demonstrating a 2.7 cycle 
difference in the expression of beta-actin between young/middle-aged and 
presenescent/senescent F344 rats. Therefore, it appears that there are fundamental 
differences in RVLM beta-actin gene expression with advancing age, although this was 
not the case when we examined RVLM beta-actin gene expression in young sham 
operated (n=3) or young SD rats experiencing heart failure (n=6) (figure 9.8B).  
Figure 9.9. Beta-actin is an Acceptable HK Gene for the Spleen, 
Cortex and PVN But Not the RVLM in F344 Rats. We have 
completed studies in the F344 and SD rat to determine if beta-
actin is a suitable HK gene for use in normalizing real-time PCR 
data. Aging did not influence beta-actin expression in the spleen, 
cortex or PVN of the F344 rat. Multiple stressors did not affect
beta-actin gene expression in the spleen, cortex and PVN of SD
rats. While beta-actin expression in the RVLM did not change
during heart failure in SD rats, aging markedly increased beta-
actin expression in the RVLM of F344 rats, demonstrating that
beta-actin is not an acceptable HK gene for use in real-time PCR 
analysis of RVLM gene expression in aging studies. 
 
 54
The variable effect of age on actin gene expression in the RVLM was unexpected 
because all previous real-time PCR experiments conducted using tissue from the 
spleen, cortex and PVN had demonstrated stable expression despite differences in 
tissue type, age or stress (figure 9.9). However, in the RVLM we observed similar 
average actin Ct values between young/middle-aged and presenescent/senescent age 
groups but not across all age groups. In fact, we observed on average, a 2.7 cycle 
difference in the average actin (Actb) Ct value between young/middle-aged and 
presenescent/senescent age groups. Of particular interest is the fact that a 2.5 cycle 
difference on average, was also observed in the RVLM of four other well-established 
Figure 9.10. HK Gene Expression is Increased With Advancing
Age in the RVLM of F344 Rats. Hprt (A), Rpl1 (B), Ldha (C) and 
Rpl13a (D) were higher in the RVLM of presenescent and
senescent F344 rats compared to young and middle-aged F344 
rats. A difference of 2.5 cycles on average exists between all
presenescent/senescent and young/middle-aged HK values, 
indicating that between 12 and 24 months of age transcriptional
regulation of genes considered to be stably expressed is
substantially altered. Therefore, these housekeeping genes, in 
addition to beta-actin, are not appropriate for normalizing real-time 
PCR data generated from aging studies using the RVLM of F344
rats.   
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housekeeping genes represented on the same array that generated the actin Ct value 
data presented here, including Hprt (hypoxanthine guanine phosphoribosyl transferase), 
Ldha (lactate dehydrogenase A), Rplp1 (60s acidic ribosomal protein P1) and Rpl13a 
(ribosomal protein L13a) (figure 9.10).  
 
Differences in housekeeping gene expression can result in the misinterpretation 
of real-time PCR studies. Standard criteria for an appropriate HK gene for normalization 
purposes are 1) abundantly expressed, 2) stably expressed in a variety of tissues, 3) 
unaffected by experimental conditions and 4) does not differ by more than 1 cycle 
between experimental groups381. Our initial studies indicated that beta-actin is a stably 
expressed gene in multiple tissues under multiple experimental conditions, including 
aging. However, beta-actin differed between young/middle-aged and 
presenescent/senescent rats by 2.7 cycles. It is standard procedure to choose an HK 
gene that does not vary by more than 1 cycle between experimental groups because 
this equates to over a 2-fold difference, the level at which many studies consider to be 
the benchmark for significance in differences in gene expression363,382. Fold change is 
generally calculated as 2^ whereby “2” accounts for the doubling of PCR product per 
amplification cycle and “^” is the cycle number.  Therefore, for every amplification cycle 
during the real-time PCR reaction, gene products double (2^1 = 2-fold change)382. The 
2.7 cycle difference in beta-actin expression that we observed between young/middle-
aged and presenescent/senescent rats is roughly equivalent to a 6.5-fold difference 
(2^2.7 = 6.5) in HK gene expression, which does not meet the requirement that a HK 
gene only vary between experimental groups by 1 cycle (or 2-fold). Therefore, use of a 
 56
HK gene with such a high fold difference between young/middle-aged and 
presenescent/senescent age groups in 2-ΔΔCt calculations would result in the failure to 
detect significant changes altogether (e.g., those over 2-fold) or in the overexaggeration 
of the magnitude of the fold-change for true differences in target gene expression 
between age groups. It is estimated that in order for a target gene to overcome such a 
difference in fold-change HK expression and be considered significant, the target gene 
would need to be up- or downregulated 8.5-fold (6.5-fold difference between HK values 
+ 2-fold benchmark for significance = 8.5-fold). This demonstrates how changes in gene 
expression that are significant when using a suitable HK for normalization may appear 
to be unchanged when using an HK gene that varies between experimental groups by 
more than 1 cycle because the large difference between HK genes (6.5-fold) will mask 
any changes that are less than 6.5-fold. The effect of using an inappropriate HK gene 
for normalization was demonstrated by Chen and coworkers when they normalized 
Cu/Zn-superoxide dismutase expression using a HK gene that was significantly 
decreased in aged rats (UBC). A significant difference in Cu/Zn-superoxide dismutase 
expression was detected between young and aged rat livers using UBC; however, use 
of an appropriate HK gene (Hprt) resulted in no difference in Cu/Zn-superoxide 
dismutase expression between age groups. A similar misinterpretation of data was 
demonstrated when catalase expression levels in the livers of young and aged rats 
were normalized to UBC. Using this approach it appeared that aged rats expressed 
31.20% less catalase than young rats; however, when catalase expression was 
normalized to Hprt, aged rats were found to express 57.73% less catalase363,364. This 
clearly illustrates how differences in HK gene expression between age groups can 
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wrongly identify changes when none exist or “mask” the degree to which actual changes 
occur.  
 
In conclusion, our studies examining RVLM beta-actin gene expression during 
aging demonstrate a limitation to our analytical approach in that we were unable to 
make pairwise comparisons in RVLM gene expression between young, middle-aged, 
presenescent and senescent F344 rats when using beta-actin as a HK gene (or Hprt, 
Rplp1, Ldha, Rpl13a) for real-time PCR experiments. However, we were able to 
quantitate RVLM gene expression profiles between young and middle-aged, and 
presenescent and senescent F344 rats using beta-actin as the normalization factor in 2-
ΔΔCt calculations because average actin Ct values only differed between young and 
middle-aged rats by 0.15 and by 1.00 between presenescent and senescent rats. This 
to our knowledge, is the first report that substantial changes occur in the transcriptional 
regulation of well established HK genes, including beta-actin, between 12 and 24 
months of age in the RVLM of F344 rats.  
 
Array-based RVLM Neurotransmitter System Gene Expression Profiling 
Beta-actin was selected as an acceptable HK gene for use in identifying changes 
in constitutive RVLM gene expression between young and middle-aged, and 
presenescent and senescent F344 rats, although it was not appropriate for making 
pairwise comparisons between young, middle-aged, presenescent and senescent rats. 
Neurotransmitter system gene expression profiling was accomplished using a rat 
Neurotransmitter Receptors and Regulators RT2 Profiler™ real-time PCR array 
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(Superarray) developed specifically for use in the Bio-Rad iCycler. This novel array 
system allows for the relative quantification of eighty-four genes involved in regulating 
the biological processes of neurotransmitter biosynthesis, uptake, transport, and 
signaling through neurotransmitter receptors, including receptors specific for GABA, 
acetylcholine, benzodiazepine, dopamine, glutamate, serotonin, somatostatin, and 
neuropeptides. Data analysis was based on the comparative Ct method (2-ΔΔCt) with 
normalization of the raw data to beta-actin. Although Suzuki and others379, in a review of 
all gene expression analyses published in 1999, found that over 90% used only one HK 
or reference gene, with beta-actin among the HK genes more widely used, only until 
recently has it been suggested that the use of more than one HK gene be included 
during normalization procedures to provide more accurate comparative Ct 
calculations364,372,383. Therefore, target gene expression was normalized to beta-actin 
alone and resultant fold-changes were validated by normalizing the data to the 
combined average Ct value of Hprt, Ldha, Rplp1 and Rpl13a (HK genes also 
represented on the array). Age-associated differences in target gene expression are 
presented as fold change and selection criteria for significance was set at a two-fold 
change, which is a widely accepted standard for the quantification of gene 
expression363,364.  
 
Young vs. MA RVLM Neurotransmitter System Gene Expression 
Although the neurotransmitter array allowed us to examine the constitutive 
expression of 84 genes in the RVLM, we found that overall, 17 out of 84 genes (20%) 
were up- or down-regulated at least two-fold in magnitude between young and middle-
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aged F344 rats. 16/17 genes (94%) were upregulated while 1/17 (6%) was down-
regulated. Of these 17 genes, we chose a select few as genes of interest due to their 
known involvement in regulation of sympathetic nerve activity and grouped them into 
themes according to their known function in the central nervous system; therefore, 
results will be discussed accordingly.  
 
GABAA Receptor Subunits: RVLM expression of GABAA receptor alpha5 subunit 
(Gabra5) decreased and GABAA receptor subunits alpha2 (LOC289606), alpha6 
(Gabra6) and theta (Gabrq) were increased in middle-aged compared to young F344 
rats. No significant differences were detected for GABAA receptor subunits alpha1,3,4 
(Gabra1, 3, 4), beta2,3 (Gabrb2-3), delta (Gabrd), epsilon (Gabre), gamma1,2 (Gabrg1-2), 
pi (Gabrp) or rho1,2 (Gabrr1-2).  
Figure 9.11. Fold-Change Differences in GABAA Receptor Subunit Expression.  
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Neurotransmitter Catabolism and Biosynthesis: Expression of choline acetyltransferase 
(Chat) and a member of the choline transporter family (Slc5a7) increased in the RVLM 
of middle-aged compared to young F344 rats. No significant (e.g., over 2-fold) change 
in 4-aminobutyrate aminotransferase (GABA-T, Abat) expression was observed. 
 
 
 
 
 
 
 
 
Muscarinic Acetylcholine Receptor Subtypes: Expression of muscarinic acetylcholine 
receptor subtype 2 (M2, Chrm2) and 5 (M5, Chrm5) increased in the RVLM of middle-
aged F344 rats compared to that of young. No significant changes were observed for 
subtypes M1 (Chrm1), M3 (Chrm3), and M4 (Chrm4).  
Figure 9.12. Fold-Change Differences 
in the Expression of Genes Involved in 
GABA Catabolism and Acetylcholine 
Synthesis.
Figure 9.13. Fold-Change Differences in Muscarinic Receptor
Subtype Expression. 
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Nicotinic Acetylcholine Receptor Subunits:  Nicotinic acetylcholine receptor alpha 
polypeptide3 (Chrna3), beta polypeptide1 (Chrnb1), and beta polypeptide4 (Chrnb4) 
gene expression increased in the RVLM of middle-aged F344 rats compared to young. 
No significant changes were observed in the expression of alpha polypeptide1,2 
(Chrna1-2) and 4-6 (Chrna4-6), beta polypeptide2 (Chrnb2), 3 (Chrnb3), or for 
polypeptides delta (Chrnd), epsilon (Chrne) or gamma (Chrng) subunits. 
 
 
 
 
 
  Figure 9.14. Fold-Change Differences in Nicotinic Receptor Subunit
Expression. 
 
Dopamine Receptor Subtypes: Dopamine receptor subtype 1a (Drd1a) expression 
increased in the RVLM of middle-aged compared to young F344 rats. No significant 
changes were observed for subtypes Drd2-5. 
Figure 9.15. Fold-Change Differences in Dopamine 
Receptor Subtype Expression. 
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Presenescent vs. Senescent RVLM Neurotransmitter System Gene Expression 
Array-based SYBR Green® real-time PCR analysis determined that overall, 36 
out of 84 genes (43%) were up- or down-regulated between presenescent and 
senescent F344 rats by at least two-fold in magnitude compared to 17/84 genes (20%) 
identified in the young/middle-aged group comparison. Of these 36 genes, we chose a 
select few as genes of interest due to their known involvement in regulation of 
sympathetic nerve activity and grouped them into themes according to their known 
function in the central nervous system; therefore, results will be discussed accordingly. 
 
GABAA Receptor Subunits: RVLM gene expression of GABAA receptor subunit alpha1 
(Gabra1), alpha6 (Gabra6), beta3 (Gabrb3), delta (Gabrd), gamma2 (Gabrg2), pi 
(Gabrp), and rho2 (Gabrr2) increased and alpha3 (Gabra3) decreased in senescent 
compared to presenescent F344 rats. No significant differences in the expression of 
alpha2 (LOC289606), Gabra4,5, Gabrb2, Gabre, Gabrg1, Gabrq and Gabrr1 were 
observed. 
Figure 9.16. Fold-Change Differences in GABAA Receptor Subunit Expression. 
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Neurotransmitter Catabolism and Biosynthesis: RVLM gene expression of 4-
aminobutyrate aminotransferase (GABA-T, Abat) and choline acetyltransferase (Chat) 
increased in senescent compared to presenescent F344 rats. No significant differences 
in Slc5a7 were observed.  
 Figure 9.17. Fold-Change Differences in 
the Expression of Genes Involved in
GABA Catabolism and Acetylcholine
Synthesis. 
 
 
Muscarinic Acetylcholine Receptor Subtypes: Expression of M1 (Chrm1) and M3 
(Chrm3) were increased in the RVLM of senescent compared to presenescent F344 
rats. No significant differences in the expression of Chrm2, 4-5 were observed. 
 
 
 
 
 Figure 9.18. Fold-Change Differences in 
Muscarinic Receptor Subtype Expression. 
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Nicotinic Acetylcholine Receptor Subunits: Alpha polypeptide1-3,5,6 (Chrna1-3, 5-6), beta 
polypeptide1,3,4 (Chrnb1, 3-4) and polypeptide epsilon (Chrne) expression increased in 
the RVLM of senescent compared to presenescent F344 rats. No significant changes in 
Chrna4, Chrnb2, Chrnd and Chrng expression were observed. 
 
 
 
 
 
 
Figure 9.19. Fold-Change Differences in Nicotinic Receptor Subunit Expression. 
 
Dopamine Receptor Subtypes: Expression of dopamine receptor subtype 1a (Drd1a) 
and dopamine receptor subtypes 3-5 (Drd3-5) increased in the RVLM of senescent 
compared to presenescent F344 rats. No significant changes in Drd2 were observed. 
 
 
 
 
 
Figure 9.20. Fold-Change Differences in 
Dopamine Receptor Subtype Expression. 
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CHAPTER 10 - Discussion 
Seven new findings concerning the effect of age on constitutive RVLM 
neurotransmitter gene expression in F344 rats are presented in the current study. First, 
of the five housekeeping (HK) genes that we examined under basal conditions (Actb, 
Hprt, Ldha, Rp1p1, Rpl13a), none demonstrated stable expression in the RVLM during 
the aging process, particularly between 12 and 24 months of age. Second, alpha1, 
alpha6, beta3, delta, gamma2, pi and rho2 GABAA receptor subunit mRNA expression 
was higher while alpha3 was lower in senescent compared to presenescent rats. 
Expression of alpha2 (LOC289606), alpha6 and theta transcripts was higher while alpha5 
was lower in middle-aged compared to young rats, demonstrating transcriptional 
regulation of GABAA receptor subunit expression is differentially altered during middle-
age and senescence. Third, GABA-transaminase (GABA-T) mRNA expression was 
higher in senescent compared to presenescent rats (young and middle-aged did not 
differ), while glutamate decarboxylase 65 and 67 (GAD65, GAD67) remained 
unchanged with age. This finding suggests potential shifts in the balance between 
GABA synthesis and metabolism in the RVLM of senescent rats. Fourth, muscarinic 
receptor subtype 1 (M1) and 3 (M3) mRNA expression was higher in senescent 
compared to presenescent rats but remained unchanged in young and middle-aged 
rats, although muscarinic receptor subtype 2 (M2) and 5 (M5) were higher in middle-
aged compared to young rats. Differential expression of muscarinic receptor subtypes 
may reflect altered muscarinic-mediated modulation of GABAergic synaptic currents in 
the RVLM of middle-aged and senescent rats. Fifth, nicotinic acetylcholine receptor 
(nAChR) subunit mRNA expression of alpha polypeptide1-3,5,6, beta polypeptide1,3,4 and 
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polypeptide epsilon was higher in senescent than presenescent rats. The expression of 
alpha polypeptide3 and beta polypeptide1,4 differed between middle-aged and young 
rats, indicating variable nAChR expression within the RVLM of middle-aged and 
senescent rats and possible heightened cholinergic transmission within the RVLM of 
senescent rats. Sixth, mRNA expression of acetylcholinesterase (Ache) was not 
substantially affected by advancing age. However, expression of choline 
acetyltransferase (Chat) and a member of the choline transporter family (Slc5a7) were 
higher in middle-aged compared to young rats and Chat mRNA was higher in senescent 
compared to presenescent rats (Slc5a7 remained unchanged). These findings 
demonstrate that age-related changes in the RVLM cholinergic system occur at the 
level of the neurotransmitter (acetylcholine) in addition to the level of the receptor 
(muscarinic and nicotinic); changes that collectively may enhance cholinergic 
transmission and influence on GABAergic synapses within the RVLM of senescent rats. 
Seventh, mRNA expression levels of dopamine receptor subtypes 1a (Drd1a), 3 (Drd3), 
4 (Drd4) and 5 (Drd5) were higher in senescent compared to presenescent rats. Of 
these subtypes, all but Drd1a remained unchanged between middle-aged (Drd1a 
higher) compared to young rats, suggesting elevated dopaminergic transmission and 
potentially, attenuation of GABAergic inhibition of RVLM neurons in senescent rats. 
Collectively, our findings suggest that differentially expressed neurotransmitter genes in 
the RVLM during aging may provide the mechanistic basis for influencing GABAergic 
synaptic transmission within the RVLM thereby potentially contributing to the 
sympathetic activation that occurs with advancing age. 
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Figure 10.1. Overview of Results from the Current Study. Progressive increases in 
SND occur with advancing age. The RVLM is a brainstem region critically involved in 
the regulation of sympathetic outflow. RVLM activity is strongly inhibited by GABAergic 
neural inputs; therefore we hypothesized that GABAergic tone is withdrawn in the 
RVLM thereby contributing to the increased SND that is associated with aging (dotted 
line text box). An array-based real-time PCR approach was used to determine the 
effects of age on constitutive GABAA receptor gene expression in the RVLM of F344 
rats. Because age affected beta-actin expression in the RVLM, target gene expression 
in young rats was compared to middle-aged rats and presenescent rats were 
compared to senescent rats. Cholinergic and dopaminergic receptor systems were 
included in our analysis due to their reported influence on GABAA receptor activity. 
The number of genes found to be significantly different (over 2-fold) between 
young/middle-aged and presenescent/senescent rats are represented in the orange 
and green boxes, respectively.  
It is well established that normal aging is associated with progressive increases 
in efferent SND87,291,296,305. Type II diabetes75-78, obesity5,40,41,384, heart failure93 and 
hypertension305 are pathologies that have been attributed to both the processes of aging 
and sympathetic dysfunction, exemplifying the importance of understanding central 
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regulation of SND during aging. The RVLM is a critical brainstem region involved in 
setting the basal level of sympathetic outflow18 and glutamatergic neurons provide the 
predominate source of excitatory input to the RVLM125,146,385. Therefore, it is possible 
that increases in sympathetic activity commonly observed in the aged are attributed to 
enhanced activity of excitatory amino acid (EAA) receptors in the RVLM. However, 
glutamatergic influences on RVLM activity are powerfully inhibited by tonic GABAergic 
neural inputs originating from the CVLM3,386; effects that are mediated by GABAA 
receptors located on presympathetic neuronal cell bodies within the RVLM208. In the 
present study we proposed that reductions in GABAA receptor subunit expression 
and/or alterations in the GABAA receptor subunit profile may reflect withdrawal of 
GABAergic tone in the RVLM thereby contributing to the basal sympathetic activation 
that occurs with advancing age. An array-based real-time PCR approach was used to 
investigate whether aging affects the constitutive expression of 19 GABAA-related gene 
products. Relative quantification of gene expression data generated from the array 
required the use of a HK gene to normalize the expression of target genes of interest in 
order to eliminate differences in the amount and quality of RNA and efficiencies of 
reverse-transcription reactions361,362. A suitable HK gene for normalization purposes 
exhibits abundant, stable expression across a variety of tissues and experimental 
conditions and does not vary between experimental groups by more than one 
cycle361,363,364,381. We examined the expression of 5 well established HK genes (Actb, 
Hprt, Ldha, Rp1p1 and Rpl13a) in the RVLM of young, middle-aged, presenescent and 
senescent F344 rats under basal conditions and found that these genes, including beta-
actin, are not stably expressed in the RVLM with age (figure 10.1). Although in the 
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current study beta-actin was previously established as an acceptable HK gene for use 
in real-time PCR studies involving the spleen, cortex and PVN of F344 and SD rats 
under various experimental conditions. We report that a 2.7 cycle difference in RVLM 
beta-actin gene expression existed between young/middle-aged and 
presenescent/senescent rats, equating to a 6.5-fold difference. In contrast, the 
difference between young and middle-aged rats was 0.15 cycle while presenescent and 
senescent rats differed by 1 cycle, indicating that while gene expression could not be 
evaluated using pairwise comparisons (e.g., young vs. middle-aged, young vs. 
presenescent, young vs. senescent), it was a suitable HK gene for use in examining the 
differences in neurotransmitter gene expression between young and middle-aged rats, 
and presenescent and senescent rats. Results from array-based real-time PCR studies 
using beta-actin as a normalization factor will be briefly discussed. 
 
GABAAR Alpha1, Beta2,3 and Gamma2. Alpha1, beta2,3 and gamma2 are the most 
abundantly expressed and widely distributed GABAA receptor subunits in the 
brain226,230,257,258,260. Immunohistochemistry studies have demonstrated that these 
subunits are frequently colocalized in the rat brain257,258,387,388; indicating that a large 
proportion of GABAA receptors in the rat brain contain alpha1, beta2,3 and gamma2 and 
suggesting that they may be of physiological importance226,257. Each of these GABAA 
receptor subunits is critically involved in insuring proper GABAA receptor function. For 
example, alpha1 and beta3 form the GABA binding site231, the beta subunit is required 
for GABAA receptor cell surface expression249-251 and gamma2 is critical for GABAA 
receptor clustering at the synapse255. Of particular relevance to the present study, 
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GABAA receptor subunits alpha1, beta2,3 and gamma2 have been shown to exhibit 
substantial overlap in pattern distribution within the brainstem258 and are expressed at 
appreciable levels in the RVLM258,260. 
 
Real-time PCR results from the current study indicate that alpha1, beta2,3 and 
gamma2 mRNA expression did not differ between young and middle-aged rats but that 
each of these subunits, with the exception of beta2, was higher in senescent compared 
to presenescent rats (+2.00, +1.95, +2.09, respectively; fold change). Senescent rats by 
definition are no longer thriving326,329,330,334,335,341 and are rapidly progressing towards 
death326,328,334,335,341. Upon the transition into senescence, F344 rats exhibit reductions 
in food intake323-326, body weight regulation337,339, thermoregulation337,339 and circadian 
rhythmicity337,339. Furthermore, senescent F344 rats die on average within three weeks 
of entering into senescence326. Therefore, it is possible that the increases in alpha1, 
beta3 and gamma2 GABAA receptor subunit expression observed in senescent rats may 
represent a RVLM GABAA receptor profile characteristic of F344 rats which are near the 
end of their natural lifespan.  
 
The increase in alpha1, beta3 and gamma2 GABAA receptor subunits in 
senescent rats may also reflect enhanced GABAergic tone in the RVLM and/or altered 
GABAA receptor function, although mRNA expression of enzymes involved in GABA 
biosynthesis (glutamate decarboxylase 65 and 67; GAD65, GAD67), did not differ 
between presenescent and sensescent rats. This implies that the GABA biosynthetic 
pathway is not substantially activated during senescence; however, mRNA expression 
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of GABA-T, an enzyme involved in the degradation of GABA, was higher (+2.09) in 
senescent than presenescent rats (it did not differ between young and middle-aged 
rats). GABA-T has previously been identified in the medulla389,390 and age-related 
increases in GABA-T have previously been demonstrated in the cerebrum and 
cerebellum of rats391,392. It is well accepted that tonic excitatory drive to the RVLM is 
balanced by the powerful inhibitory activity of GABA-containing axonal projections from 
the CVLM and that these actions are mediated by RVLM GABAA receptors. Normal 
aging is associated with elevated SND, suggesting potential withdrawal of CVLM 
GABAergic inhibition of sympathetic output. It is tempting to speculate that the 
transcriptional upregulation of alpha1, beta3 and gamma2 GABAA receptor subunits in 
the RVLM of senescent rats occurs in response to age-associated reductions in CVLM 
GABAergic influence in an effort to dampen the sympathoexcitatory state during aging. 
On the other hand, although GABA-T does not necessarily indicate enhanced 
enzymatic degradation of GABA, increases in RVLM GABA-T could suggest reductions 
in GABA availability for inhibitory synaptic transmission. Under these circumstances, 
GABA-T may mediate withdrawal of CVLM inhibitory inputs to the RVLM, thereby 
shifting the balance towards sympathoexcitation in senescent rats (figure 10.2).  
 
Other GABAAR Subunits. Alpha2-6, gamma1, delta, epsilon, pi, rho and theta GABAA 
receptor subunits are not abundantly or widely expressed in the brain230,258,393. For 
example, alpha2 expression is primarily confined to the forebrain and compared to 
alpha1, is not highly expressed in the brainstem260. Gamma1 is preferentially distributed 
in the amygdala, substantia nigra and inferior olive230. Rho and alpha6 GABAA receptor 
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subunit expression is reportedly limited to the retina393, and cerebellum and cochlear 
nucleus, respectively230. Immunohistochemistry studies in the adult rat brain have 
revealed the RVLM has little to no alpha2,4 or gamma1; low expression of alpha5; 
moderate levels of alpha3, beta2,3 and delta, and high levels of gamma2258,260.  Results 
from the present study determined that of the GABAA receptor subunits that are 
considered to be less abundantly expressed in the brain, alpha2 (LOC289606; +4.64), 
alpha6 (+2.02) and theta (+4.69) mRNA expression was higher and alpha5 (-2.15) was 
lower in middle-aged compared to young rats. Senescent rats displayed higher levels of 
alpha6 (+2.05), delta (+4.70), pi (+2.14) and rho2 (+3.65) but lower levels of alpha3 (-
2.19) compared to presenescent rats. These findings demonstrate differential 
transcriptional regulation of RVLM GABAA receptor subunits at two separate timepoints 
in the aging process of F344 rats (e.g., middle-age and senescence); however, the 
physiological implications of these age-related alterations are currently unclear.  
 
Xenopus oocytes expressing either alpha1/beta, alpha2/beta or alpha3/beta 
subunit combinations have half-maximal responses at 10μM, 1μM and more than 10μM 
concentrations of GABA, respectively394; suggesting that GABAA receptors containing 
alpha2 subunits may exert more potent synaptic inhibition than those receptor subtypes 
containing alpha1 or alpha3. Therefore, it is possible that in our study higher alpha2 
mRNA levels indicate preferential expression of a more GABA-sensitive GABAA 
receptor subtype in the RVLM of middle-aged rats. Reportedly, GABAA receptors 
containing the delta subunit have intensified responses to GABA395 and muscimol396 
and may associate with alpha1,3, beta2,3 and gamma2 subunits. It may be considered 
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that the higher levels of delta, alpha1, beta3 and gamma2 GABAA receptor subunit 
transcripts in senescent rats may contribute to the formation of a GABAA receptor 
subtype that contains a combination of delta, alpha1, beta3 or gamma2 subunits and is 
capable of enhancing inhibitory responses in the RVLM. Senescent rats also expressed 
more GABAA receptor subunit rho transcripts. At present, rho subunits are not believed 
to coassemble with other GABAA receptor subtypes393,397 but are thought to form homo- 
and hetero-oligomeric channels that are similar to GABAC receptors259,398-400.  GABAC 
receptors are ligand-gated ion channels that are activated at lower concentrations of 
GABA and are less sensitive to desensitization compared to GABAA receptors401,402; 
therefore it is possible that increased rho2 strengthens inhibition of synaptic activity in 
the RVLM of senescent rats. Our results clearly demonstrate that during senescence 
GABAA receptor subunits that impart increased sensitivity to GABA and resistance to 
receptor desensitization are transcriptionally upregulated. It is tempting to speculate that 
the upregulation of alpha1, beta3, gamma2, delta and rho2 subunits leads to more 
pronounced GABAergic synaptic transmission between the CVLM and RVLM in 
senescent rats. Elevations in CVLM GABAergic synaptic transmission may be mediated 
by increases in the expression of GABAA receptors that resist desensitization and elicit 
more potent responses to GABA binding, thereby enhancing GABAergic tone in the 
RVLM of senescent rats. The fact that we observed increases in the transcription of 
GABA-T may imply that this is a counter-regulatory response under conditions 
characterized by enhancements in both CVLM activity and GABAA receptor expression 
and sensitivity in the RVLM. Therefore, if inhibitory influences are not being regulated at 
the level of the CVLM or at the receptor level in the RVLM (e.g., downregulation of 
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Figure 10.2. GABA-T May Contribute to Elevated SND During
Aging: A Hypothetical Model. The CVLM provides tonic
inhibitory input to the RVLM thereby decreasing SND.
However, in the senescent rat both GABAA receptors and 
GABA-T were upregulated. Increased GABAA receptor 
expression may indicate enhanced inhibitory tone within the
RVLM; however, GABA-T may effectively reduce the activity 
level of GABAA receptors by limiting the availability of GABA
released from CVLM neurons. This may contribute to
withdrawal of GABAergic tone and shift the basal level of
activity towards excitation within the RVLM of senescent rats. 
GABAA receptors or alterations in receptor subtype in response to elevated CVLM 
activity), increased GABA-T 
may act as a “safety-switch” 
by which such powerful and 
potentially harmful inhibition 
may be dampened through 
increased enzymatic 
degradation of GABA at 
GABAergic synapses in the 
RVLM, an action that may 
effectively shift the RVLM 
towards a level of excitation 
(figure 10.2). 
 
 
 
In the current study, the use of a commercially available real-time PCR array 
provided us the ability to effectively screen the RVLM transcriptome for 19 GABAA-
related and 65 neurotransmitter-related genes and identify those which demonstrate 
changes associated with age, the identities of which may provide the biological basis for 
central mechanisms that contribute to progressive elevations in SND associated with 
normal aging. Although we primarily focused on constitutive RVLM GABAA receptor 
expression in the present study, the array provided us the opportunity to explore several 
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different neurotransmitter systems reported to influence GABAergic function including, 
muscarinic, nicotinic and dopaminergic. Expression of genes within each of these 
systems was found to change with age. Those that changed by at least two-fold will be 
briefly discussed below. 
 
Muscarinic Receptor Subtypes. Of the cholinergic (acetylcholine) receptors in the brain, 
muscarinic receptors are the most abundant357. Inhibitory and excitatory responses to 
acetylcholine are mediated by the metabotropic muscarinic receptor357 and it is well 
established that central muscarinic systems undergo substantial alterations in 
experimental animals and humans with advancing age403. For example, changes in 
receptor binding properties and regional distribution of muscarinic receptor subtypes 
occur during aging403-405, suggesting potential contributions to altered cholinergic 
transmission and cholinergic function403,406. Of particular relevance to the present study, 
pharmacological, immunohistochemical, real-time PCR and in situ hybridization 
methodologies have been used to confirm M1, M2, M3, M4 and M5 muscarinic receptor 
expression in the rat RVLM374,407. Moreover, peripheral administration of the 
acetylcholinesterase inhibitor physostigmine or microionotophoretic application of 
acetylcholine increases the firing rate of RVLM neurons, a response that is mediated in 
part by the M2 muscarinic receptor408-412. The role of acetylcholine in pressor responses 
is further demonstrated following microinjection of physostigmine directly into the RVLM. 
Increases in MAP, acetylcholine release and choline acetyltransferase (Chat, an 
enzyme involved in acetylcholine synthesis) activity in the RVLM are observed at 
greater levels in spontaneously hypertensive rats (SHR) than normotensive Wistar-
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Kyoto (WKY) rats, indicating that acetylcholine in the RVLM contributes to the 
maintenance of elevated MAP in hypertensive animals413,414. Because hypertension is 
commonly associated with increased sympathetic outflow305, we suggest acetylcholine 
may contribute in part to the sympathetic activation that occurs in the aged. Evidence 
supports the presence of tonically active cholinergic inputs that potentiate sympathetic 
outflow in the RVLM217,407,410,411,415-420. Our studies revealed that in the RVLM, 
transcripts for muscarinic receptor subtypes M2 (+2.06) and M5 (+2.52) were higher in 
middle-aged than in young rats while M1 (+2.70) and M3 (+2.14) were found to be 
higher in senescent compared to presenescent rats. In addition, we report that 
expression levels of Chat and a choline transporter (Slc5a7, involved in acetylcholine 
synthesis) were higher in middle-aged rats while Chat expression levels were higher in 
senescent rats. Collectively, our results indicate that the muscarinic receptor expression 
profile in the RVLM is variably affected with aging which may contribute to altered 
cholinergic transmission and elevated sympathetic outflow in middle-aged and 
senescent rats (figure 10.3). It is also possible that the muscarinic receptor profiles 
represent altered modulation of sympathetic vasomotor responses to baroreflex 
activation with advancing age. Indeed, the baroreflex influences cholinergic responses 
to increases in MAPP421 because intravenous administration of phenylephrine increases 
acetylcholine release in the RVLM in a baroreceptor-dependent manner and 
glutamatergic excitation of the CVLM elicits acetylcholine release in the RVLM421. The 
presence of muscarinic receptors on GABAergic interneurons may provide yet another 
mechanism by which MAP is centrally regulated422. Burst synchronization is reportedly 
affected by the activation of muscarinic receptors located on GABAergic interneurons423 
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and acetylcholine has been shown to reduce GABA release and block GABAergic 
synaptic currents in the auditory cortex422,424. Of particular relevance to the current study 
are the findings that M1 and M2 muscarinic receptors potently attenuate GABAergic 
inhibition422. Although this phenomonen was described in corticopetal fibers422, perhaps 
similar mechanisms occur in the RVLM of middle-aged and senescent rats because 
they expressed higher levels of M2 and M1, respectively. Therefore it is possible that 
these receptor subtypes in the RVLM blunt GABA signaling in the RVLM (figure 10.3); 
however, the precise role of M1 and M2 muscarinic receptors in the RVLM is unclear. 
Furthermore, muscarinic receptor modulation of GABA  receptor function may be 
dependent on brain region or cell type due to differences in muscarinic and GABA  
receptor subtype, distribution and functional properties. 
A
A
  
 
 
 
 
 
 
 
 Figure 10.3. RVLM Muscarinic Receptor Expression May Mediate Increased 
Sympathetic Outflow in the Aged: A Hypothetical Model. Both middle-aged and 
senescent rats had higher levels of muscarinic receptor expression than young and
presenscent rats, respectively. Muscarinic receptors mediate sympathoexcitation 
and pressor responses to acetylcholine in the RVLM. This may provide a 
mechanism by which SND is elevated with advancing age. 
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Nicotinic Acetylcholine Receptors. Nicotinic acetylcholine receptors are members of the 
super-family of ligand-gated ion channels that includes GABAA receptors425. Pentameric 
in structure, the alpha subunit contributes to the formation of a ligand binding site and 
determines functional properties of the receptor357. Diffusely distributed throughout the 
brain, alpha4 and beta2 are the most abundantly expressed nicotinic receptor 
subunits426-428. Neurons can express more than one nicotinic receptor subtype at both 
pre- and post-synaptic terminals357,428, however the composition of native receptors is 
currently unknown357. Real-time PCR analysis from the current study demonstrated that 
alpha polypeptide3 and beta polypeptide1,4 transcript levels were higher in middle-aged 
than in young rats. Senescent rats expressed higher levels of alpha polypeptide1-3,5,6, 
beta polypeptide1,3,4 and polypeptide epsilon compared to presenescent rats. The 
impact of these changes on SND regulation in both middle-age and senescent rats is 
unclear because at the present time the structural composition of nicotinic receptors and 
their functional diversity has not been well established357. Although we did not detect 
marked changes in alpha4 subunit expression, Dehkordi and others have demonstrated 
that alpha4-containing nicotinic receptors are located on GABAergic neurons in the 
RVLM429. This may provide insight into the potential physiological relevance of elevated 
levels of alpha3, beta1 and beta4 nicotinic receptor subunits in middle-aged rats and 
alpha1-3,5,6, beta1,3,4 and epsilon in senescent rats.  Evidence suggests that pre- and 
postsynaptic nicotinic receptors can inhibit the release of GABA and inhibit GABAA 
receptors, respectively428; therefore, it is possible that nicotinic receptors located on the 
cell bodies of RVLM neurons may serve to regulate the degree by which GABA-
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containing CVLM projections influence RVLM activity and that this mechanism may lead 
to elevations in efferent SND in the aged (figure 10.4). 
 
 
 
 
 
 
 
 
 
Figure 10.4. Nicotinic Receptors May Attenuate GABAergic Inhibition of Efferent
SND: A Hypothetical Model. Nicotinic receptors may contribute to SND activation with
advancing age by inhibiting the release of GABA from axons that project from the
CVLM and synapse with presympathetic nerve cell bodies in the RVLM. The increase
in GABAA receptor expression that we observed in the RVLM of senescent rats may
not represent enhanced GABAergic tone in the RVLM because nicotinic receptors
may also inhibit GABAA receptor activity. 
 
 
 
 
Dopamine Receptor Subtypes. Metabotropic dopamine receptors mediate a number of 
neurochemical and physiological processes357. Dopamine receptor subtype expression 
displays regional selectivity in the adult rat brain357 and it is believed that L-DOPA, a 
precursor for dopamine, is a central neurotransmitter/neuromodulator that is released 
from neurons to elicit pre- and post-synaptic responses430. Microinjection studies have 
demonstrated that application of L-DOPA into the RVLM increases MAP and heart rate 
in rats431-433, suggesting that dopamine may modulate SND outflow and arterial 
pressure support.  In the lower brainstem L-DOPA promotes GABA release432 which in 
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turn tonically inhibits L-DOPA release and hypertensive responses to L-DOPA430,432. 
Importantly, these effects are mediated by GABAA receptors430,432. Results from our 
study indicate that dopamine receptor subtype 1A mRNA expression was higher in 
middle-aged rats (+2.12) compared to young rats and that dopamine receptor subtype 
1A (+2.09), 3 (+2.14) and 5 (+2.41) expression was higher in senescent rats compared 
to presenescent rats.  
 
While the physiological significance of these age-related alterations is currently 
unclear, it is possible that they may reflect dopaminergic function and/or modulation of 
GABA release in the RVLM of senescent rats. Several lines of evidence suggest that 
interactions between D1, D3, D5 and GABAA receptors exist and that such interactions 
contribute to altered dopaminergic and GABAergic neuronal transmission. First, D1 
receptors are the most abundantly expressed dopamine receptor in the brain and have 
been shown to colocalize with D3 receptors in neurons434. Second, D3 and D5 receptors 
have 20- and 10-fold higher affinity for dopamine than D2 and D1 receptors, 
respectively434,435, suggesting that responses to dopamine may be markedly enhanced 
in senescent rats. Third, the cytoplasmic tail of D5 receptors associates with the GABAA 
receptor subunit gamma2436; an interaction that effectively inhibits the signaling 
capability of the other437. Fourth, D3 activation attenuates the GABAergic synaptic 
current in the nucleus accumbuns through reductions in the cell surface expression of 
the GABAA receptor beta subunit, suggesting that D3-mediated suppression of GABA 
responsiveness occurs through the internalization of GABAA receptors438. Therefore, it 
may be considered that increased expression of D1, D3 and D5 receptors in the RVLM 
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reflects a point of regulation for controlling GABAA receptor responses to CVLM neural 
inputs in senescent rats by potentially reducing the release of GABA from CVLM axonal 
terminals and/or downregulating GABAA receptor cell surface expression in 
presympathetic neuronal cell bodies within the RVLM. It is tempting to speculate that 
these hypothetical consequences of dopamine-GABAA receptor interactions may serve 
as an additional “safety switch” (in addition to GABA-T as discussed previously) that 
serves to counteract potential increases in CVLM activity that may occur during 
senescence, thereby withdrawing inhibitory influences and shifting the balance towards 
the sympathoexcitatory state that is commonly observed with advanced age (figure 
10.5). 
 
 
 
 
 
 
 
 
  
 
 
The use of a “pathway-focused” (e.g., neurotransmitter-related) real-time PCR 
array is an attractive approach to scanning the F344 RVLM for function-specific genes 
Figure 10.5. Dopamine Receptors May Increase Sympathetic Outflow by
Impairing GABAergic Signaling: A Hypothetical Model. Dopamine receptors in the 
RVLM may inhibit GABA release from the CVLM and promote internalization of
GABAA receptors which would influence the basal level of efferent SND in
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of interest. In the current study we found variable age-related alterations in the mRNA 
expression profiles of GABAA, muscarinic, nicotinic and dopaminergic receptor systems 
in the RVLM of young/middle-aged and presenescent/senescent F344 rats. Several 
factors may explain the non-uniformity in expression patterns that we observed in the 
RVLM of middle-aged and senescent rats when compared to young and presenescent 
rats, respectively. First, specific genes may exhibit inherent differences in their 
sensitivity to the aging process, potentially affecting mRNA stability as well as 
transcriptional processes. Second, changes in the expression of individual subunits and 
therefore, receptor subtype expression, may reflect an age-dependent adaptation to 
physiological events that are occurring and/or may be specific to a particular 
chronological or biological age. Indeed, an important advantage to receptor 
compositional heterogeneity is the functional flexibility that it provides through 
alterations in cell surface or synaptic localization, binding kinetics, desensitization, 
channel gating or signal transduction properties and modulation by pharmacological 
agents. However, it is important to note that changes in the gene expression of a 
particular receptor subunit or subtype that we observed in the current study may not 
necessarily indicate similar changes in the protein or the incorporation of that protein 
into mature receptor complexes. There are at least three limitations to the present 
study. First, anesthesia may influence neurotransmitter system gene expression, 
particularly that related to GABAA,  although the majority of studies investigating RVLM 
function have used anesthetized preparations439 and preliminary experiments 
completed in our laboratory have demonstrated that expression levels of GABAA 
receptor subunit alpha1 protein do not markedly differ between young, middle-aged and 
 83
presenescent F344 rats treated with or without 5% isofluorane anesthesia. Second, the 
sympathetic nervous system is capable of producing regionally selective changes in 
sympathetic outflow and it is well established that in the brain molecular changes in 
neurotransmitter expression and function are often times region-specific226,230,258,260,440-
445. Therefore, the results from the present study are only applicable to the RVLM of 
F344 rats and may not necessarily be indicative of similar changes in other autonomic 
regions. Third, because we used a focused genomic approach to examine constitutive 
neurotransmitter gene expression in the RVLM, our findings only represent changes 
that occur at the mRNA level and may not accurately reflect a similar level of protein 
expression446-450. Despite these limitations; however, our experimental approach 
successfully met our objective of rapidly and comprehensively screening a large number 
of genes related to GABAA receptor subunits, enzymes involved in GABA synthesis and 
metabolism, and other neurotransmitter systems in a quantitative manner. The present 
study, to our knowledge, is the first to undertake the task of comprehensively 
characterizing the constitutive expression of multiple neurotransmitter systems in the 
RVLM of F344 rats and to examine the effect of age on the expression of these 
systems. Therefore, the results presented herein provide many genes that may be of 
potential interest to scientists in the aging, cardiovascular physiology, endocrine and 
autonomic neurophysiology research communities. Future studies employing 
biochemical, electrophysiological, pharmacological and molecular biological 
methodologies will be necessary to determine the physiological relevance of these 
changes in the RVLM. 
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 Appendix A - Real-time PCR Data Supplemental Material 
Gene Young Middle-Aged Presenescent Senescent 
Abat 27.98 ± 0.98 28.18 ± 1.52 25.93 ± 0.78 25.87 ± 0.50 
Gad1 29.30 ± 1.32 29.03 ± 1.35 26.57 ± 0.86 27.30 ± 0.93 
Gad2 28.50 ± 0.69 28.20 ± 1.09 26.80 ± 0.40 26.90 ± 0.72 
Gabra1 30.02 ± 1.26 30.28 ± 2.03 27.80 ± 0.97 27.80 ± 0.36 
LOC289606 31.94 ± 0.94 29.58 ± 1.23 28.53 ± 1.05 29.50 ± 0.71 
Gabra3 33.72 ± 0.62 34.20 ± 0.45 32.50 ± 1.07 34.63 ± 0.37 
Gabra4 32.70 ± 1.02 32.05 ± 1.14 30.20 ± 1.04 30.67 ± 0.81 
Gabra5 30.62 ± 0.97 31.58 ± 1.28 28.53 ± 1.06 29.07 ± 0.46 
Gabra6 30.14 ± 1.03 28.98 ± 0.59 31.40 31.37 ± 2.69 
Gabrb2 29.78 ± 0.96 29.75 ± 1.79 27.53 ± 1.04 27.93 ± 0.12 
Gabrb3 29.24 ± 1.06 29.40 ± 1.39 27.23 ± 0.87 27.27 ± 0.64 
Gabrd 33.16 ± 0.59 32.45 ± 1.12 31.73 ± 0.56 30.50 ± 1.45 
Gabre 34.32 ± 0.68 33.80 ± 0.75 32.37 ± 0.89 33.87 ± 1.13 
Gabrg1 30.92 ± 1.14 30.98 ± 1.46 28.63 ± 0.71 29.00 ± 0.76 
Gabrg2 29.68 ± 1.16 28.93 ± 1.48 26.80 ± 0.90 26.73 ± 0.44 
Gabrp 34.38 ± 0.62 33.95 ± 0.61 33.07 ± 0.61 32.97 ± 0.32 
Gabrq 32.98 ± 0.86 30.60 ± 1.17 29.97 ± 0.29 31.57 ± 0.98 
Gabrr1 34.12 ± 0.29 33.58 ± 0.93 34.03 ± 0.48 34.23 ± 0.41 
Gabrr2 34.98 ± 0.02 35.00 35.00 34.13 ± 0.44 
Ache 28.98 ± 1.10 28.23 ± 1.66 26.40 ± 1.07 27.03 ± 0.69 
Chat 33.10 ± 1.43 30.95 ± 2.21 30.73 ± 2.54 29.90 ± 1.85 
Slc5a7 31.72 ± 1.79 29.25 ± 2.33 28.47 ± 1.70 28.80 ± 1.96 
Chrm1 34.94 ± 0.06 33.90 ± 0.67 34.57 ± 0.38 34.13 ± 0.77 
Chrm2 31.34 ± 0.69 30.15 ± 1.02 30.77 ± 0.97 31.23 ± 0.74 
Chrm3 32.96 ± 0.52 33.15 ± 1.21 31.47 ± 0.82 31.37 ± 0.64 
Chrm4 34.92 ± 0.08 34.20 ± 0.77 33.23 ± 0.64 33.87 ± 0.98 
Chrm5 33.96 ± 0.41 32.48 ± 0.55 33.23 ± 0.26 34.80 ± 0.15 
Chrna1 34.42 ± 0.58 33.95 ± 1.05 33.93 ± 0.75 32.73 ± 0.97 
Chrna2 34.46 ± 0.33 33.60 ± 1.04 34.03 ± 0.55 32.93 ± 0.73 
Chrna3 33.88 ± 0.84 32.75 ± 1.14 32.83 ± 1.17 31.77 ± 0.88 
Chrna4 31.84 ± 1.04 32.25 ± 1.52 29.43 ± 0.79 30.50 ± 0.89 
Chrna5 34.06 ± 0.61 33.90 ± 0.71 33.97 ± 0.54 33.43 ± 1.27 
Chrna6 35.00 34.58 ± 0.33 34.90 ± 0.10 34.90 ± 0.10 
Chrnb1 33.34 ± 0.55 31.68 ± 0.67 31.93 ± 0.33 31.73 ± 0.43 
Chrnb2 31.84 ± 0.93 31.68 ± 1.79 29.90 ± 1.06 30.03 ± 0.54 
Chrnb3 34.84 ± 0.16 34.90 ± 0.10 35.00 35.00 
Chrnb4 34.34 ± 0.66 33.08 ± 1.09 33.30 ± 1.08 32.97 ± 0.48 
Chrnd 32.14 ± 0.42 31.33 ± 0.98 33.90 ± 0.59 33.97 ± 1.03 
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Chrne 34.68 ± 0.27 34.20 ± 0.80 33.00 ± 0.36 32.80 ± 0.49 
Chrng 29.94 ± 0.56 29.25 ± 0.79 30.27 ± 0.35 31.93 ± 0.19 
Comt 31.48 ± 1.25 30.65 ± 2.01 28.20 ± 0.96 28.53 ± 0.19 
Maoa 30.22 ± 1.27 30.28 ± 1.70 27.23 ± 0.89 27.50 ± 0.49 
Th 33.26 ± 0.75 32.13 ± 1.05 31.17 ± 0.87 32.43 ± 1.49 
Drd1a 34.56 ± 0.22 33.33 ± 0.75 34.27 ± 0.53 34.20 ± 0.80 
Drd2 30.68 ± 0.53 30.70 ± 0.77 29.53 ± 0.83 30.10 ± 0.66 
Drd3 34.60 ± 0.26 34.10 ± 0.39 33.97 ± 0.71 33.87 ± 0.57 
Drd4 35.00 34.65 ± 0.22 35.00 35.00 
Drd5 34.98 ± 0.02 34.78 ± 0.23 34.77 ± 0.23 34.50 ± 0.40 
Actb 24.50 ± 1.08 24.35 ± 1.55 21.23 ± 0.64 22.23 ± 0.35 
Ldha 30.44 ± 1.37 29.95 ± 1.44 26.77 ± 0.77 28.40 ± 0.95 
Rplp1 24.92 ± 0.91 24.93 ± 1.35 21.93 ± 0.73 22.37 ± 0.41 
Rpl13a 25.88 ± 0.99 26.43 ± 1.36 23.50 ± 0.87 24.67 ± 0.55 
Hprt 28.92 ± 1.20 28.98 ± 1.29 26.23 ± 0.89 26.93 ± 0.79 
 
 
 
Table A.1. Mean threshold cycle (Ct) values for select target genes of interest and five 
HK genes examined in the present study. Values presented are not normalized to a HK 
gene. Young n=5, Middle-aged n=4, Presenescent n=3 and Senescent n=3 F344 rats.
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